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Abstract 
A key decision in scientific work is whether to build on novel or well-established ideas. Because 
exploiting new ideas is often harder than more conventional science, novel work can be especially 
dependent on interactions with colleagues, the training environment, and ready access to potential 
collaborators. Location may thus influence the tendency to pursue work that is close to the edge 
of the scientific frontier in the sense that it builds on recent ideas. We calculate for each nation its 
position relative to the edge of the scientific frontier by measuring its propensity to build on 
relatively new ideas in biomedical research. Text analysis of 20+ million publications shows that 
the United States and South Korea have the highest tendencies for novel science. China has become 
a leader in favoring newer ideas when working with basic science ideas and research tools, but is 
still slow to adopt new clinical ideas. Many locations remain far behind the leaders in terms of 
their tendency to work with novel ideas, indicating that the world is far from flat in this regard. 
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1. Introduction 
 
Knowledge production is an increasingly global endeavor. In spite of robust increases in 
scientific production by the traditional leaders – including the United States, the United 
Kingdom, and Japan – their relative share has decreased in recent decades because the pace of 
growth in science by other nations – including China, South Korea, India, and Brazil – has been 
even more rapid (Freeman, 2013; National Science Board, 2016). The share of international 
collaborations has also increased, as has the share of citations to papers with foreign authors 
(Freeman, 2013, National Science Board, 2016). This spread of knowledge production has not 
been unexpected. It was anticipated long ago by Marshall (1920) that improved communication 
technologies would make it easier to learn about new discoveries regardless of location and that 
this would lead to the pursuit of creative work in more diverse places. 
While this perspective suggests a diminishing influence for location in scientific work, 
location may in fact continue to have considerable import in science. This is because learning 
about which new ideas exist may not have been an important benefit of location for quite some 
time and because location likely still impacts the fertility of creative work in other important 
ways. Lucas (2004), for example, has emphasized the continuing dependence of knowledge 
production activities on location through the benefits that accrue from daily interactions with 
colleagues, the training environment, and ready access collaborators.  
One potential remaining influence of location stems from the fact that when new ideas 
are first discovered, they are often raw and poorly understood. The ideas only gradually mature 
into useful advances after a community of scientists tries them out and develops them. But such 
work is hard, harder than work that builds on well-established ideas. One indication that work 
that tries out new ideas is indeed harder than more conventional science is that such work is 
linked with larger team size (Packalen and Bhattacharya, 2016). Thus, when a scientist seeks to 
build on a recent advance, it is beneficial to be surrounded by a community of scholars with 
whom to debate about which new ideas to try out and how (Marshall, 1920; Kuhn, 1962, 1977; 
Usher, 1929). Daily interactions with colleagues, the training environment, and ready access to 
potential collaborators thus become especially important in work that is close to the edge of the 
scientific frontier in the sense that the work builds on recent advances. 
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Because such local factors influence the fertility of the debates that seek to unlock the 
mysteries of new ideas, the tendency to work with new ideas can be expected to vary by location. 
This mechanism – and thus the import of location – may even be increasingly influential, for 
Jones (2010) shows that reaching the scientific frontier now involves even more work than 
before as evidenced by increases in training times, specialization, and teamwork.  
Therefore, even as the pursuit of science spreads to more diverse places, location may 
well continue to have an important influence on what kind of science is pursued – through the 
impact that location may have on the ability to work with novel ideas.  Identifying where barriers 
to knowledge adoption still exist is thus crucial for understanding the role of location in 
knowledge production and for designing policies that can help eliminate the remaining barriers.  
We calculate each nation’s propensity to publish biomedical work that is close to the edge 
of the scientific frontier in the sense that it builds on relatively recent ideas. The results reveal 
each nation’s position on the scientific frontier: what share of its contributions to biomedical 
science build on relatively new ideas vs. well-established ideas. Our empirical analysis is 
focused on biomedicine because it is an important area of science and because of the availability 
of the Pubmed/MEDLINE database on over 24 million biomedical research papers.  
We refer to our constructed measure of novelty as the edge factor. Whereas the familiar 
impact factor measures scientific influence (Garfield, 1955, 1972), the edge factor measures an 
aspect of novelty of scientific work – the tendency to build on ideas close to the edge of the 
scientific frontier. A common characteristic for these two measures is that for each entity they 
both quantify the average of a characteristic (rather than the total number of novel contributions 
or the total number of received citations). 
We selected countries as the unit of analysis because borders continue to influence 
scientist interactions and because many important science policy decisions are set at the national 
level. However, similar to the impact factor, the edge factor too can be constructed also for many 
other units of analyses. For example, the approach can be utilized to evaluate the novelty of 
research published by a journal or institution. It can also be applied to analyze the novelty of 
individual scientists’ publications and examine which scientist-level characteristics promote the 
trying out of new ideas. Furthermore, the edge factor can be utilized to compare to what extent 
funding agencies succeed in their often-stated aim of supporting novel work. The focus on 
countries in the present paper is thus just one possible application. But this focus is useful 
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because it provides way to utilize this concept – the edge factor – to shed light on a long-standing 
question about to what extent the spread of modern communication technologies has eradicated 
location-based barriers to the adoption of new ideas. At the same time, this application illustrates 
the potential of the edge factor in other contexts.  
We emphasize that the impact factor and the edge factor capture distinct aspects of 
science – impact and novelty – regardless of the specific setting in which they are employed. 
Moreover, the edge factor and the impact factor are complementary tools in policy evaluation 
and design. For optimal science policy requires that both influence and novelty are rewarded. 
One reason why rewarding influence alone is not enough is that rewarding novelty directly helps 
solve a coordination problem that is inherent in the formation of a vibrant scientific community 
to a new area of investigation (Besancenot and Vranceaunu, 2015; Packalen and Bhattacharya, 
2017). A singular focus on citation counts can lead to stagnant science because impact factors 
under-reward scientists who try out new ideas, thereby stifling work that helps ideas mature and 
makes more meaningful advances possible. Another related reason to reward novel work is that 
useful work that tries out a new idea need not be influential in the traditional sense; such work 
can have scientific value – in terms of helping unlock the mysteries of the new idea – even when 
it merely demonstrates which research paths do not work.  
In recent decades, many – including the editor of Science (Alberts, 2013) – have raised 
alarm about the science community’s obsession with impact factors. The obsession with impact 
may have already led to less healthy science, as the rise of citation metrics has coincided with a 
decline in the novelty of biomedicine (Rzhetzky et al., 2015). By using measures like the edge 
factor in conjunction with impact-based metrics, university administrators and funding agencies 
can strike a better balance between rewarding innovative but risky work that develops ideas early 
on and rewarding work that takes advantage of the ideas in their more mature stages. Making 
reward structures even slightly more favorable to scientific novelty would encourage scientists to 
pursue more innovative research paths and lead to healthier, less stagnant, science. To be sure, 
the edge factor is not meant to displace the impact factor. Instead, it is ideally used as a 
complementary metric that captures a different aspect of science. 
As in the closest prior work (Packalen and Bhattacharya, 2017), the focus here is on the 
novelty of idea inputs, as opposed to the novelty of the combination of idea inputs. Novelty of 
combinations is a focus in several recent analyses (Wang et al., 2016; Lee et al., 2015; Rzhetzky 
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et al., 2015; Boudreau et al., 2016; Foster et al., 2015). Both foci come with their advantages, as 
discussed in Packalen and Bhattacharya (2017). The focus on the use of new ideas makes it 
possible to include on a larger number of ideas in the analysis than is computationally feasible in 
an analysis of combinatorial novelty. Analysis of the use of new ideas is also important because 
the trying out of new ideas is so central to scientific progress. For without new ideas science 
eventually stagnates – combinatorial novelty alone cannot overcome it. 
Similar to the closest prior work (Packalen and Bhattacharya, 2017)., we use text analysis 
to determine the ideas that each paper built upon and also the vintage of those ideas. There are 
two main differences between the present study and this prior work. First, there is a shift in 
substantive focus – from ranking journals to ranking nations. Second, in the present approach the 
novelty of each contribution is allowed to depend not just on the vintage of ideas employed in it 
but also on what types of ideas they are. This is important because a paper that employs a 10-
year old research tool may represent novel work but the same need not be true for a paper that 
examines a gene of the same vintage. This methodological innovation yields a more finely 
grained measurement of each entity’s distance to the edge of the scientific frontier. Importantly, 
this methodological advance can be utilized in various applications beyond the present analysis. 
 
 
2. Methods 
 
In this section, we first describe the data sources (MEDLINE biomedical publications database, 
NLM Journal Categories, the UMLS Metathesaurus, and the MeSH vocabulary). In subsection 
2.2 we explain why the analysis is focused on years 1988-2016, and in subsection 2.3 we explain 
why the location of each contribution is determined based on the first author’s affiliation. In 
subsection 2.4 we explain how the research area of each contribution is determined.  
In subsection 2.5 we explain how we use the UMLS metathesaurus to determine the ideas 
that each paper built upon and also how the vintage of each idea is determined. In subsection 2.6 
we explain how we define a contribution (by determining links from each paper to each research 
area and each idea category), how we measure the idea category of each idea based on the 
UMLS metathesaurus, why the resulting contribution-level analysis is preferable to a paper-level 
analysis, and also how the novelty of each contribution is determined. 
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In subsection 2.7 we explain how the overall edge factor for each nation is calculated: we 
first determine the nation’s edge factor separately for each (idea category, research area) pair 
based on all the nation’s contributions linked to that pair; afterwards we calculate the nation’s 
overall edge factor as a weighted sum of its edge factors across all (idea category, research area) 
pairs. Finally, in subsection 2.8 we explain how the approach developed here differs from the 
approach used in closest prior work.  
 
2.1 Data Sources 
 
2.1.1 MEDLINE Database on Biomedical Research Publications 
 
Our source for information on scientific publications is the MEDLINE database 
(https://www.nlm.nih.gov/bsd/pmresources.html). MEDLINE is a comprehensive database on 
life sciences with a focus on biomedicine in particular. The database contains information on 
over 24 million journal articles. 
For each journal article in MEDLINE, we make use the following variables: publication 
year, affiliation of the first author, text of the title and abstract, journal where the article was 
published, and MeSH keywords. The acronym “MeSH” stands for Medical Subject Headings; 
the MeSH vocabulary is a controlled vocabulary of over 87,000 terms 
(https://www.nlm.nih.gov/mesh/). Publications in MEDLINE indexed with MeSH keywords; we 
use the MeSH keywords to determine article type (we focus the analysis on original research 
articles) and whether an article represents applied or basic science (section 2.4). 
 
2.1.2 Broad Subject Terms for MEDLINE Journals 
 
Our source for the research area of each article is the broad subject terms that are assigned by the 
National Library of Medicine for journals in the MEDLINE database 
(https://wwwcf.nlm.nih.gov/serials/journals/index.cfm). We show further below how articles in 
the MEDLINE database are distributed across the journal categories in this database (section 
2.4).     
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2.1.3 Unified Medical Language System (UMLS) Metathesaurus 
 
As our source for information on which words and word sequences represent meaningful 
concepts in biomedicine and which concepts are synonyms, we use the 2017 version of the 
Unified Medical Language System (UMLS) metathesaurus 
(https://www.nlm.nih.gov/research/umls/). The UMLS metathesaurus links over 5 million terms 
that appear in one or more of over 150 medical vocabularies. 
In addition to determining the synonyms for each term, the UMLS database assigns each 
term to one or more of 127 semantic types (https://semanticnetwork.nlm.nih.gov). We use the 
semantic type of each term to represent the idea category of the term (section 2.6.1). Further 
below we list examples of ideas and idea categories captured by this approach (section 2.6.2). 
 
2.2 Sample of Papers 
 
When we determine the vintage of each idea (section 2.5.2), we use the sample of all 
papers in the MEDLINE database. By contrast, when we calculate for each location its 
propensity to publish novel work, we limit the sample of papers in several ways. First, we limit 
the analysis to original research papers, thereby excluding editorials, reviews, etc. However, in a 
robustness analysis, we include all papers in the sample. Second, we limit the analysis to papers 
published during 1988-2016. This is because the coverage for affiliation data in the MEDLINE 
database begins in 1988. Third, we limit the analysis to papers for which the available text on the 
title and the abstract of the article in the database includes at least 200 characters and no more 
than 5000 characters. However, in a robustness analysis, we conduct the analysis without this 
character limit. The number of articles that are included in our main specification is shown by 
publication year in Figure S1 (Web Appendix).  
 
2.3 Country of Each Scientific Publication 
 
We assign each paper to a country based on the affiliation string for the first author of the paper. 
We limit the analysis to first authors because for most papers published before 2014 the 
affiliation information in MEDLINE is limited to the first author of each paper. Figure S2 (Web 
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Appendix) shows by publication year the share of papers that we were able to match to a 
country. For ease of exposition we limit the number of locations by combining some countries 
that publish a smaller number of biomedical publications to regions. Figure S3 (Web Appendix) 
shows the share of papers by location (country or region) and time period. 
 
2.4 Journal Categories and Journal Category Groups 
 
We use the journal categories (Broad Subject Terms) to represent the research area of each 
paper. On average, each original research article published during 2015-2016 is linked to 1.49 
journal categories. Table S1 (Web Appendix) shows the distribution of links from papers to 
journal categories during this time period. As is discussed in detail further below (section 2.6.1), 
papers from journals that are linked to multiple journal categories are considered to have 
contributed to multiple research areas. 
In our main specification, all journal categories are included in the analysis. In secondary 
analyses, we conduct three separate analyses – each limits the analysis to one of the following 
three groups of journal categories: “Applied”, “Basic Science”, and “Other (Both Applied and 
Basic Science)”. 
To conduct these secondary analyses, we assign each journal category to one of the three 
journal category groups. Here we make use of the MeSH keywords affixed to each MEDLINE 
article and the “A-C-H” model (Weber, 2014) that classifies papers along the translational axis 
based on the MeSH keywords. Specifically, using the MeSH codes we first determine each 
paper’s position on the translational axis as specified by the A-C-H model: “H status” (human) is 
assigned to papers with either the MeSH code B01.050.150.900.649.801. 400.112.400.400 
(Human) or the Mesh code M01 (Person),  “C status” (cells and molecules) is assigned to papers 
with any of the following MeSH codes (or codes that appear in the MeSH subtrees of these 
MesH codes): A11 (Cells), B02 (Archaea), B03 (Bacteria), B04 (Viruses), G02.111.570 
(Molecular Structures), and G02.149 (Chemical Processes), and “A status” (animal) is assigned 
to papers with the MeSH code B01 (Eukaryota) and papers with any of the codes in the subtree 
of this MeSH code B01 except the aforementioned MeSH code for “Human”. 
We thus construct three separate indicator variables (“H status”, “A status”, “C status”). 
In the A-C-H model, papers with “H status” have an applied aspect to them, and papers with 
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either “A status” or “C status” have a basic science aspect to them. More than one of these 
indicator variables will be positive for papers that have both an applied and a basic science 
aspect to them.  
For each journal category, we next calculate the average of each of these three dummy 
variables (“H status”, “A status”, “C status”) among all papers linked to that journal category. 
Denoting these variables as “Average H status”, “Average A status”, and “Average C status”, we 
use them to classify journal categories to three journal category groups as follows.  Journal 
categories that satisfy conditions “Average H status > Average C status” and “Average H status 
> 0.2” are assigned to journal category group “Applied”. Journal categories that satisfy “Average 
H status < Average C status” and “Average A status < 0.8” and “Average C status > 0.5” are 
assigned to journal category group “Basic Science”. (We thus exclude journal categories that 
focus heavily on veterinary medicine from this category even though such journal categories are 
located early along the translational axis in the A-C-H model; this happens in the A-C-H model 
because the model does not distinguish between veterinary medicine and animal studies as pre-
cursor to human medicine). The remaining journal categories are assigned to journal group 
category “Other (Both Applied and Basic Science)”. The result of this approach for determining 
the journal category group of each journal category is shown in the last column of Table S1.  
 
2.5 Identifying Ideas and the Vintage of Ideas 
 
2.5.1 Using the UMLS metathesaurus to identify ideas from text 
 
We employ text analysis to discern which ideas each research paper built upon. We treat each of 
the 5+ million terms in the comprehensive United Medical Language System (UMLS) meta-
thesaurus as representing ideas. To identify which of these ideas each research paper in the 
MEDLINE database built upon, we search the title and abstract of each publication for all the 
terms in the UMLS metathesaurus.  
Thus, the first step in the text analysis is to determine for each article in the MEDLINE 
database which UMLS terms appear in it. Further below we also show a list of examples of ideas 
identified by this approach (section 2.6.2). 
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2.5.2 Calculating the vintage of each idea 
 
The vintage of the idea represented by a UMLS term is determined based on how long ago the 
UMLS term was first mentioned in a biomedical research paper. We interpret the mention of a 
relatively new term as indicative of work that builds on ideas close to the edge of the scientific 
frontier. We refer to the year of first appearance of a term as the cohort year of the term. In a 
robustness analysis, we set the cohort year of each term as the earliest year the UMLS term or 
any of its synonyms appears in the MEDLINE data (synonyms are determined based on the 
synonym information in the UMLS metathesaurus). The results from this robustness analysis 
show that our results are not driven by relabeling of old ideas. 
Because of the sparsity of publications in MEDLINE with a publication year before 1946, 
the cohort year of ideas (i.e. the year of first appearance) does not reflect the ideas’ true vintage 
well for ideas that are new to biomedicine before 1950. Thus, we exclude from the analysis all 
terms with cohort before 1950. 
Further below we show examples of cohort years assigned to terms using this approach 
(section 2.6.2).  
 
2.6 Contribution-Level Analysis  
 
2.6.1 Defining a contribution as a link from a paper to an (idea category, research area) 
pair 
 
In determining the novelty of biomedical work, we seek to control for the idea category of each 
idea. Thus, we aim to compare the use of novel ideas against the use of more established ideas 
from the same idea category. The rationale for seeking to control for the idea category is the 
following: how recent ideas should be considered novel depends on what type of an idea it is. 
For example, a paper that employs a 10-year old research tool may represent novel work but the 
same need not be true for a paper that examines a gene of the same vintage.  
To control for the idea category in the present analysis, we take advantage of the fact that 
the UMLS metathesaurus classifies terms to 127 semantic types (these are listed further below in 
section 2.6.2). We treat each of these UMLS semantic types as representing one idea category. 
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We make use of these idea categories as follows. After determining which UMLS terms 
are mentioned in each paper, we determine which UMLS categories are represented by these 
terms. We then treat a paper that mentions terms from K different idea categories as K separate 
contributions. The underlying assumption in this approach is that work that mentions at least one 
idea from an idea category advances our understanding of how ideas from that idea category 
work. Thus, work that mentions ideas from multiple categories advances our understanding on 
multiple dimensions; hence we treat it as multiple contributions. 
Table S2 (Web Appendix) shows the number of links to each idea category from papers 
published during 2015-2016. As was mentioned above in section 2.5.2, we only include in the 
analysis those terms that have cohort year 1950 or later. 
In our main analysis, we calculate the overall edge factor based on links to any of the 127 
idea categories (the edge factor is an average across all idea categories). In a secondary analysis, 
we calculate the edge factor separately for each of the following four groupings of idea 
categories: “Clinical and Anatomy”, “Drugs and Chemicals”, “Basic Science and Research 
Tools”, and “Miscellaneous”. To conduct this analysis, we link each idea category to one of 
these four idea category groups. The last column of Table S2 shows which idea category belongs 
to which idea category group. This secondary analysis reveals for each country whether any 
barriers to new idea adoption are limited by to certain types of ideas. The decision to link each of 
the 127 idea categories to one of four groups was made for expositional purposes – it implies that 
for each country we must report four separate numbers. 
What kind of work should be considered novel is likely to depend also on the research 
area. For example, use of a 10-year old research tool may be novel work in public health 
research but not in biotechnology research. To address this issue, we also determine the links 
from papers to research areas. We use the National Library of Medicine (NLM) journal 
categories as proxies for research areas (these journal categories were listed in section 2.4, Table 
S1). 
Thus, after determining the ideas mentioned in each paper, we determine which idea 
categories are linked to these ideas as well as which research areas are linked to the journal 
where the paper is published. We define a contribution as an (idea category, research area) pair 
linked to a paper. 
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In our approach, a paper is considered to contribute to our understanding of all the (idea 
category, research area) pairs linked to it. A paper can make multiple contributions, depending 
on how many (idea category, research area) pairs are linked to it. A paper that mentions ideas 
from K idea categories, and is published in a journal that is linked to J journal categories, is 
treated as K*J separate contributions. 
Note that a paper that mentions multiple ideas from an idea category results in the same 
number contributions as a paper that mentions only one idea from the idea category. 
The number of links listed in the second column of Table S1 is the number of links to 
(idea category, research area) pairs associated with each research area. Similarly, the number of 
links listed in the second column of Table S2 is the number of links to (idea category, research 
area) pairs associated with each idea category. On average, each paper published during 2015-
2016 is linked to linked to 6.26 (idea category, research area) pairs. Therefore, in our approach 
each paper is, on average, counted as 6.26 contributions. 
A limitation of the approach pursued here is the inherent assumption that, synonyms 
aside, all ideas within an idea category are treated as though they are equally close to one another 
although in reality some are closer than others. Similarly, all ideas within a category are treated 
as though they are equally distance is the same to all ideas outside the idea category. A 
potentially important direction for future work is to explore a more fine-grained approach that 
either calculates a pairwise between each idea category or calculates a pairwise distance between 
each idea.  
When determining whether a contribution represents novel work, we only consider the 
age of the newest term linked to the (idea category, research area) pair from the paper in 
question. Researcher’s choice is between using any new ideas or only well-established ideas 
from this idea category. This is discussed in more detail next. 
 
2.6.2 The novelty of a contribution 
 
Above we defined a contribution as a link from a paper to an (idea category, research area) pair; 
these links are inferred from the UMLS terms that appear in the title and abstract of the paper. 
The novelty of each contribution is determined in three steps. 
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Step 1. Age of each UMLS term that links a paper to the (idea category, research area) 
pair. First, for each contribution associated with a paper, we determine the age of each term that 
links the paper to the (idea category, research area) pair in question. Age of each term is 
calculated by subtracting the cohort year of the term from the publication year of the paper. 
Step 2. Age of the newest UMLS term that links a paper to the (idea category, research 
area) pair. Second, for each contribution we determine the age of the newest term that links the 
paper to the (idea category, research area) pair. We refer to the cohort year of the newest term 
that links a paper to the (idea category, research area) pair as the cohort year of the contribution. 
Step 3. Novelty of the contribution relative to other contributions to the (idea category, 
research area) pair among papers published in the same year. The relative novelty of a 
contribution is then determined by comparing the vintage of the contribution to the vintages of 
all the other contributions linked to the same (idea category, research area) pair, among papers 
published in the same year. The interpretation is that a paper that links to an idea category 
reflects a choice faced by a scientist: one can choose work with at least one relatively new idea 
from this idea category, or one can choose to work with only well-established ideas from this 
idea category. The comparison is also limited by research area because whether the use of an 
idea represents novel work is expected to depend on the context where it is used. The reason for 
limiting the comparison to papers published in the same year is obvious: because the rate of 
scientific progress need not be the same over time, the use of a 10-year old research tool may 
represent novel work in one year but not in some other year.   
Having determined all contributions linked to an (idea category, research area) pair 
among papers published in the same year, we order the contributions based on their vintage (age 
of the newest term linked to that (idea category, research area) pair from each paper). We then 
construct an indicator variable that captures the relative novelty of each contribution: in our 
baseline specification, contributions that are in the top 5% based on their vintage are considered 
novel work (the indicator variable is 1 for such contributions and 0 otherwise). In robustness 
analyses, we construct the indicator variable using alternative choices for the cutoff percentile 
(top 1%, top 5%, or top 20%). Figure S4 (Web Appendix) shows the distribution of the cohort of 
all contributions based on papers published during 2015-2016.  Figure S5 (Web Appendix) in 
turn shows the distribution of cohort of novel contributions when novelty of a contribution is 
determined based on the top 5% status and also the when novelty of a contribution is determined 
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based on one of the alternative cutoffs (top 20%, top 10%, or top 1%). When the top 5% cutoff is 
used, then for all post-2004 cohorts the majority of contributions with that cohort are deemed 
novel by our approach, and for all pre-2004 cohorts at most a minority of contributions are 
deemed novel by our approach.  
Table S3 (Web Appendix) shows examples of ideas, as represented by UMLS terms, 
captured by our approach. The table also shows the idea category of each term. Some terms 
appear multiple times because these terms are linked to multiple UMLS categories by the UMLS 
metathesaurus. As in related prior work (15), the list of terms shows that the approach used here 
captures ideas that are widely recognized to have been important inputs in biomedical work in 
recent decades (for expositional reasons the list is focused on popular ideas – there are of course 
also many unpopular, less important ideas that are captured by our approach) and that for most 
terms the cohort year assigned to the term reflects the era when the idea represented by the term 
entered biomedicine. 
 
2.7 Calculation of the Edge Factor  
 
2.7.1 Novelty of a nation’s contributions linked to a specific each (idea category, research 
area) pair 
 
Normalization of contribution-level novelty indicators. Having determined the contributions of 
each paper (i.e. which (idea category, research area) pairs are linked to from each paper) and 
which contributions are novel (i.e. which contributions have the top 5% status based on their 
vintage), we next normalize the novelty variable within contributions to each (idea category, 
research area) pair so that the average of the normalized novelty variable is 100 within each (idea 
category, research area) pair. In implementing the normalization, we combine data from multiple 
years. For example, in our main specification we combine data from 2015-2016. 
Location-level novelty scores for each (idea category, research area) pair. Using the 
normalized contribution-level novelty variable, we then calculate for each location its propensity 
for novel work within each (idea category, research area) pair. That is, for each location we 
calculate the mean of the normalized novelty variable based on all of the location’s contributions 
linked to a specific (idea category, research area) pair. We refer to each such average of the 
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novelty variables as the edge factor of the location for the specific (idea category, research area) 
pair. An edge factor above (below) 100 indicates an above (below) average tendency for work 
that builds on relatively novel ideas. In our main specification, these edge factors are calculated 
based on papers published during 2015-1016. 
 
2.7.2 Calculating the overall edge factor  
 
Having determined the relative novelty of each location’s contributions separately for each (idea 
category, research area) pair – the location’s edge factor for that (idea category, research area) 
pair – we construct the overall edge factor for each nation as a weighted sum of these (idea 
category, research area) pair specific edge scores.  
Weights. In our main specification, we use as weights the frequency at which each (idea 
category, research area) pair is encountered in biomedicine. In other words, the weight of an 
edge factor for an (idea category, research area) pair is the total number of papers linked to it 
from any location during the time period.  
A justification for selecting these weights is that those (idea category, research area) pairs 
that are encountered more often in biomedicine are, by revealed preference, considered more 
important by scientists. The ability to pursue cutting-edge work in an often-encountered (idea 
category, research area) pair is thus arguably more valuable than is the ability to pursue cutting-
edge work in a rarely encountered (idea category, research area) pair. The implicit assumption in 
this approach is that, even though it is not yet known which (idea category, research area) pairs 
will be the most important sources of future progress in biomedicine, the past is the best 
predictor of the future.  
Because the overall scientific frontier position for a nation (the edge factor) is calculated 
as a weighted sum over its position across all (idea category, research area) pairs, the resulting 
measure for the nation reflects its overall capability across all of biomedicine, as opposed to only 
the nation’s capabilities in areas where it has concentrated most of its own activities. 
Accordingly, the edge factor is high only if the country has significant capabilities across 
different areas of biomedicine; expertise in a narrow subset of biomedicine is not enough. 
However, in a secondary analysis we show that the results are robust to the case when the 
edge factor is calculated using as weights each country’s own number of papers that link to a 
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given (idea category, research area) pair. Hence, the results from this alternative specification 
reflect the novelty of the work actually pursued by the nation – emphasizing more the novelty of 
the nation’s work in areas where it publishes a lot – rather than the nation’s capabilities across all 
of biomedicine.  
Cells with missing observations. Not all locations have publications linked to every (idea 
category, research area) pair. The results are mainly insensitive to how such missing cells are 
handled. One reason for this is that while there are 13,394 (idea category, research area) pairs 
with positive weights, the 3,000 largest (idea category, research area) pairs as measured by their 
weight account for the vast majority (82%) of the total weight with most of them large enough 
for also the small and mid-sized nations to be active in them. In our main specification, we 
handle the cells with missing observations by replacing the nation’s edge factor for that cell with 
the nation’s weighted average across the other cells (those (idea category, research area) pairs for 
which the location does have publications linked to it). The weights used in this calculation are 
the same weights as discussed above. In an alternative specification, we replace cells with 
missing edge scores with 0 (the worst possible edge score). In another alternative specification, 
we replace cells with missing edge scores with 100 (by definition the average novelty score for 
every (idea category, research area) pair). In both cases the results are similar to the results for 
the main specification (see section 3.2). 
 
2.8 Comparison of the Approach with the Approach Used in Closest Prior Work 
 
The approach employed here has two main differences with the closest prior work (Packalen and 
Bhattacharya, 2017). In addition to the shift in substantive focus – from ranking journals to 
ranking nations –  the present analysis is conducted at the contribution-level, with contribution 
defined as a link from a paper to an (idea category, research area) pair. By contrast, in this prior 
work, the analysis was conducted at the paper-level. That is, here the novelty score for an entity 
is calculated first at the contribution-level separately for each (idea category, research area) pair 
and the overall novelty score for the entity is then calculated as a weighted sum across these each 
(idea category, research area) pairs. By contrast, in the prior work (Packalen and Bhattacharya, 
2017) the novelty score for an entity was calculated at the paper-level either without controlling 
for either the idea category or the research area, or by only controlling for the research in a 
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manner that essentially uses as weights the entity’s own involvement in the research area (in this 
prior work the research area was determined based on the appearance of 6-digit MeSH terms; the 
entity of interest in this prior work was a journal, here it is a nation). 
The advantage of the approach pursued in the present analysis is thus not only that the 
present approach controls for the idea category but also that the present approach uses as weights 
the (idea category, research area) pair’s overall importance in biomedicine (as measured by the 
total number of contributions linked to it). This yields a better reflection of an entity’s 
capabilities in biomedicine compared to the case when the weights represent the distribution of 
the entity’s own involvement across different areas of biomedicine. 
 
 
3. Results 
 
3.1 Main Results 
 
Figure 1 shows the edge factor for each nation based on papers published during 2015-2016. The 
edge factor is normalized so that the average edge factor across all contributions is 100. An edge 
factor of 110 for a nation indicates that on average the nation’s contributions build on relatively 
new ideas 10% more often compared to the average contribution in the same research area. 
Markers drawn in red (blue) indicate edge factors that are well above (well below) average. 
Markers drawn in gray indicate edge factors that are approximately average. 
The results show that the United States and South Korea have the most advanced 
positions on the scientific frontier: scientists working in these nations build on cutting-edge ideas 
more often than do scientists in other locations. The propensity for novel science is well above 
average also in Singapore and Taiwan. Countries that come after these four countries have 
approximately average propensity for novel science. Such countries include China, Canada, most 
western European countries (including the United Kingdom and Germany), Australia, and South 
Africa. Other countries (including Turkey, India, Brazil, and Iran) come further behind – 
scientists in these countries have clearly below average propensities for novel work. 
Confidence intervals and results for alternative specifications (shown in Table S4 (Web 
Appendix) and discussed in detail below in subsection 3.2) indicate that in most cases these 
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results are robust. The one exception is Saudi Arabia, for which results from alternative 
specifications suggest a below average tendency for novel work.  
Countries examined here thus have quite different propensities for work with newer ideas 
in biomedicine. This indicates that location continues to exert considerable influence on what 
kind of science is pursued. Furthermore, even developed nations are not on an equal footing in 
the pursuit of novel scientific work: in some developed nations scientists take advantage of 
opportunities created by the arrival of new ideas much more often than do scientists in other 
nations. 
Figure 2 shows the change in the edge factor for each nation from the 1990s to present. 
South Korea, Taiwan, and China have leapfrogged most developed nations. Whereas the United 
States is still among the leaders, the relative positions of Switzerland and the United Kingdom 
are less advanced now than they were in the 1990s. Overall some convergence appears to have 
taken place as the lagging nations are no longer as far behind the leaders. This suggests that the 
world of ideas may have become somewhat flatter. Analysis of the edge factor by 5-year time 
periods (shown in Table S5 (Web Appendix)) indicates that most changes that occur are 
persistent. The changes thus reflect systematic changes in capabilities rather than merely year-to-
year random variations.  
In our approach, we compare each contribution only to other contributions that use ideas 
from the same idea category and are linked to the same research area (the 127 idea categories 
include “Amino Acid, Peptide, or Protein” and “Pharmacologic Substance”; the 125 research 
areas include “Biochemistry” and “Neoplasms”; see Table S1 and Table S2 for the full lists). 
Table 1 shows the edge factor separately for four groupings of idea categories: “Clinical and 
Anatomy”, “Drugs and Chemicals”, “Basic Science and Research Tools”, and “Miscellaneous”, 
and for three groupings of research areas: “Applied”, “Basic Science”, and “Other (Both Applied 
and Basic Science)”. 
For most nations, the edge factor is similar across these groupings, suggesting that the 
pursuit of novel work is generally dependent on capabilities that some countries possess but 
others lack. One important exception is China. China’s contributions linked to the idea category 
grouping “Basic Science and Research Tools” now have the second highest propensity for novel 
work (after Singapore), but its contributions linked to idea category groupings “Clinical and 
Anatomy” and “Drugs and Chemicals” are well below average in terms of their novelty. This 
	 19	
result serves to highlight an important feature of our approach: it can be used to reveal not just 
whether a nation is facing barriers in new idea adoption but where in the idea space those 
barriers lie.  
While in Table 1 we divided papers to just three groups based on their research area (i.e. 
basic, applied, and other), it is important to note that the restriction to just three bins on this 
dimension was made for expositional purposes. The edge factors can also be reported separately 
for each of the 125 research areas (listed in Table S2). For example, funding agencies could use 
such field-level analyses of novelty across to determine in which scientific fields their own 
country is closest to the frontier and use this information (in conjunction with other relevant 
metrics) when deciding where to allocate limited research dollars.      
 
3.2 Confidence Intervals and Results from Alternative Specifications 
 
Table S4 (Web Appendix) shows the confidence intervals and results from a variety of 
alternative specifications. For ease of comparison, the results from the main specification are 
reported again in column (1d).  
Confidence intervals reported column (1e) are constructed using a bootstrap method. We 
first generate each of 1000 artificial samples by re-sampling with replacement from the (idea 
category, research area) pairs until the total weighted number of observations (i.e. contributions) 
in each constructed sample is at least as large as the total weighted number of observations is in 
the original sample. Next, we calculate the edge factor for each nation in each constructed 
artificial sample. We then eliminate the largest 2.5% and the smallest 2.5% of the values in the 
edge factor distribution for each nation among these constructed bootstrapped samples. The 
extremes of remaining edge factor values form the 95% confidence interval for the edge factor of 
each nation. 
The calculated confidence intervals indicate that scientists in the four top nations are 
clearly above average in their propensity to use new ideas, that scientists in most developed 
nations have approximately an average propensity to use new ideas, and that scientists in 
developing nations have a below average propensity to use new ideas. 
The analysis reported in column (2) differs from the main specification in terms of how 
those (idea category, research area) pairs are treated for which a nation has no contributions 
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linked to it: now the edge factor for such (idea category, research area) pairs are replaced with 0, 
reflecting the most pessimistic scenario about the nation’s capabilities for that (idea category, 
research area) pair. By contrast, in the main specification these missing observations are replaced 
with the average edge score for the nation for (idea category, research area) pairs for which the 
nation does have observations. Comparison of the main results (column 1c) against the results in 
column (2) shows that while the edge factor decreases somewhat for the smaller nations (as 
expected), the results remain qualitatively unchanged. The fact that regardless of the approach 
the nations near the top of the rankings included also smaller and medium sized nations (in terms 
of their scientific output, as indicated by Table S3), and the fact that some larger countries are far 
down in the rankings (most notably India), demonstrate that the results are not driven solely by 
the size of a country’s scientific workforce.   
The analysis reported in column (3) differs from the main specification in how the 
weights for the edge factor for each (idea category, research area pair) are calculated. Here, for 
each country the weight for an (idea category, research area) pair is the country’s own total 
number of research publications linked to the same (idea category, research area) pair. Thus, the 
overall edge factor is the same as the average of the nation’s novelty scores across all of its 
contributions. By contrast, in the main specification weight for each (idea category, research 
area) pair is the same for all nations: it is the total number of papers linked to that (idea category, 
research area) pair. Comparison of the main results (column 1) against the results reported in 
column (3) shows that the results are robust to this alternative specification. 
The analyses reported in columns (4-6) differ from the main specification in that the 
dummy variable indicating novelty of a contribution is now constructed using top 20%, top 10% 
and top 1% cutoffs. By contrast, in the main specification this dummy variable is constructed 
using the top 5% cutoff. Comparison of the main results (column 1) against results reported in 
columns (4-6) indicates that while the main results are qualitatively robust – leaders do better 
than laggards regardless of the measure – the relative position of the United States improves as 
one moves to a narrower cutoff (from 5% to 1%) and China’s relative position improves when 
one moves to a wider cutoff (from 5% to 10% and 10% to 20%). A possible explanation is that 
countries may differ in terms of how many of their institutions are on the very edge of the 
frontier (“the bleeding edge”), so that some countries to fare better when novelty is calculated 
based on a narrower measure. For example, the U.S. may have many of the very top institutions 
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in the world (in terms of their tendency to work with new ideas) but most of its institutions may 
be further down in the pack. In another country, such as China, institutions may be more 
homogenous in terms of the scientists’ tendency to work with new ideas. The differences may 
also be driven by variation in where the new ideas are first born (the United States may be 
disproportionately the origin of new ideas – and thus receive a disproportionate share of the very 
first mentions of new terms – but scientists working in China may be relatively more eager to 
build on the new ideas). 
The analysis reported in column (7) differs from the main specification in that now the 
cohort of each UMLS term is the year of the earliest mention of that term or any of its synonyms, 
with synonyms specified by the UMLS. In contrast, in the main specification the cohort year is 
the year of the earliest mention of the term itself. Comparison of the main results (column 1) 
against the results reported in column (7) shows that the conclusions from the main specification 
are robust in this way as well. 
The analysis reported in column (8) differs from the main specification in that the 
analysis now includes all publications in MEDLINE as opposed to only regular research articles. 
The analysis reported in column (9) in turn differs from the main specification in that the 
analysis now includes also publications for which the text information on the title and abstract is 
less than 200 characters or more than 5000 characters – in the main specification such 
publications were excluded from the analysis. Comparison of the main results (column 1) against 
the results reported in columns (8) and (9) show that the results are robust also to these 
alternative specifications. 
 
 
4. Discussion 
 
While our results show that differences persist even among developed nations in their propensity 
to work with new ideas, the results do not reveal the specific mechanisms driving these 
differences. One potential driver of these cross-locational differences stems from the difficulty of 
working with new ideas. Because novel science is harder than conventional science, novel 
science is more dependent on interactions with colleagues. The fertility of these scientist 
interactions depends on factors such as the extent of complementary tacit knowledge that is 
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embedded in people and is transferred to others in meetings (Lucas 2004; Lucas and Moll, 2014). 
Cross-national variation in the extent and depth of human capital investments can thus lead to 
cross-national variation in the tendency to adopt new ideas. 
Of course, not all fruitful interactions are limited by location, as is evidenced by the fact 
that a quarter of science now involves international collaborations (Freeman, 2013; National 
Science Board, 2016). However, the rise of long-distance collaborations can also be a source of 
cross-national differences in new idea adoption: a nation can gain an advantage if its scientists 
can form distant collaborations relatively easily. In this regard, China’s special relationship with 
the United States in science (Freeman and Huang, 2015) has likely helped propel it to the 
scientific frontier. An important topic for future work is to explore to what extent Chinese 
scientists working at the frontier started their work in the U.S. This link would potentially have 
major implications for other nations that are seeking to advance their position relative to the 
scientific frontier. A related topic worthy of future exploration is quantifying to what extent 
national borders still limit collaboration opportunities and what are the implications of 
collaboration barriers for each country in terms of the novelty of its scientific output.  
Willingness to try out new ideas can vary by location also due to differences in scientist 
demographics. For example, given that early-career scientists are the most likely to work with 
new ideas (Packalen and Bhattacharya, 2016), and given that the increase in the extent of science 
in China is so recent and thus many of its scientists are early on their careers, the novelty of 
science in China may be driven in part by the youth of its scientists. Cross-national differences in 
new idea adoption and China’s remarkably ability to leapfrog in this regard may also be driven in 
part by differences in incentives to pursue novel work: it has long been understood that nations 
without vested interests in existing technologies have an elevated incentive to explore new ideas 
(Brezis et al., 1993; Mokyr, 1994). Some of the variation in new idea adoption can also be driven 
by variation in where the ideas are first born, and by remaining delays in the spread of awareness 
about which new ideas exist. 
Our results are consistent with findings from Hidalgo and Hausman (2009) which 
measured the complexity of each country’s production structure based on its exports and found 
large differences in the capabilities of nations. Their analysis was motivated by the idea that each 
nation’s capabilities determine the input varieties that it can fruitfully use in production. Our 
work, by contrast, is motivated by the idea that capabilities determine whether a nation’s 
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scientists can take advantage of the opportunities created by the arrival of new ideas. Moreover, 
whereas in this related work the complexity of goods production is measured indirectly based on 
exports, the edge factor is calculated directly based on the measured idea inputs. Common to 
these analyses is the belief that the capabilities of a nation affect which inputs it uses and both 
analyses are aimed at constructing new measures that reflect those capabilities. 
Our finding that nations continue to differ in their ability to pursue novel science is in line 
with cross-country comparisons of scientific impact as measured by citations (Freeman, 2013; 
National Science Board, 2016). The ability to take advantage of scientific opportunities 
continues to vary across locations in spite of the “death of distance” phenomenon, because 
locational differences in capabilities persist as shown by Jones et al. (2008), Agrawal and 
Goldfarb (2008), Ding et al. (2010) and Packalen and Bhattacharya (2015). 
But some aspects of our results also differ from the results obtained through traditional 
analyses of scientific productivity. Data on the tendency to produce highly cited papers point to 
the United States as a leader that remains far ahead of most western European nations and even 
further ahead of South Korea, Taiwan and China (Freeman, 2013; National Science Board, 2016; 
Freeman and Huang, 2015; Bornmann et al., 2017; Yu et al., 2014). Our analysis on the use of 
new ideas, by contrast, suggests that South Korea, Taiwan and China have caught up with 
western Europe and are now close to the United States in terms of their tendency to work with 
cutting-edge ideas. Moreover, we find that China is now a leader in favoring newer ideas when 
working with new basic science ideas and research tools. 
The finding that some countries are among the leaders in terms of their edge factor but 
lag in terms of their impact is not surprising. Prior studies have found novelty and impact to 
correlate only imperfectly (Packalen and Bhattacharya, 2017; Wang et al., 2016; Lee et al., 
2015). Moreover, work on an idea early – when the idea is still raw – may well have less impact 
than work that builds on more established ideas which properties are better understood. The early 
work on the idea is still crucial: it helps the idea develop and thus makes more significant 
advances possible. Moreover, countries investing heavily in novel science can reap significant 
benefits also for themselves from their focus: early work on an idea can help the country develop 
capabilities that enable it to take advantage of the later, more fertile, opportunities linked to the 
same idea. 
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5. Conclusion 
 
Our analysis has shown that countries continue to differ in their ability to take advantage of 
cutting-edge ideas. Even across developed nations, sizable differences persist in terms of the 
tendency at which each nation’s scientists build on recent advances. Hence, in spite of the arrival 
of modern communication technologies – which now facilitate almost instantaneous access to 
each new idea from almost anywhere in the world – the world of ideas is not yet flat. A likely 
explanation for this is that access to an idea does not guarantee that a scientist can take advantage 
of it in a productive way soon after its initial discovery. Instead, because new ideas are often raw 
and poorly understood, the ability to fruitfully build upon an idea depends on local factors such 
as daily interactions with colleagues, the training environment, and ready access to potential 
collaborators. Because these factors vary across locations but are beneficial or even necessary in 
helping scientists unlock the mysteries of new ideas, geographic differences in the tendency to 
exploit new ideas continue to persist. 
 Currently, the tendency to build on new ideas in biomedicine is highest in United States 
and South Korea. While China has leapfrogged most developed nations in terms of its overall 
tendency to work with new ideas, this progress has been uneven across idea types. In terms of 
applying basic science ideas, China has already caught up with the leaders, but in terms of 
applying new clinical knowledge, China remains below average. This result highlights an 
important benefit of the approach developed here: the approach can be used to show not only 
whether differences in new idea adoption persist, but also where in the idea space any remaining 
barriers lie. 
An important direction for future work is to examine what are the best approaches for 
overcoming barriers in idea adoption. For example, it would be useful to uncover whether the 
scientific frontier is best reached through an approach where resources are first directed to a 
handful of fields or universities or through a more diversified approach, and whether smaller 
countries can elect to specialize in narrow areas or whether the unpredictability of where in the 
ideas space important future advances come from render it necessary for even smaller countries 
to develop and maintain broad capabilities so that they can take early advantage of new advances 
no matter where in the idea space those yet unforeseen new advances are born. 
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Extending the analysis to patent data would also be useful as it would facilitate 
exploration of links between scientific frontier positions and technological frontier positions. 
Such analysis could reveal to what extent funding scientists working near the edge of the 
scientific frontier is a pre-condition for a country to obtain the capability to pursue inventions 
near the edge of the technological frontier – inventions that build on recent scientific and 
technological advances.  
 In analyses of science, the metric introduced here – the edge factor – holds considerable 
potential beyond cross-national comparisons. Ever since Garfield (1955, 1972), the focus in 
empirical analyses of knowledge production has been on measuring influence. This focus on 
impact in science policy has recently been decried by many, including Alberts (2013) and 
Osterloh and Frey (2015). For the theory of knowledge production implies that science policy 
decisions should be guided by not just the influence of scientific work but also what kind of 
science is being pursued – novel or conventional (Kuhn 1962; Besancenot and Vranceanu 2015). 
Because new ideas are raw when they are first born, they need the attention and revision by 
many scientists to mature into useful advances. But such work is risky, and without explicit 
incentives for novel work, too many choose to pursue well-trodden research paths in areas where 
many other scientists also work and thus the prospects of receiving citations are better. A 
potential consequence of excessive focus on impact is thus that science becomes stagnant, a 
phenomenon which appears to have already occurred in biomedicine (Rzhetzky et al., 2015). 
Of course, given the absence of metrics that capture novelty, the obsession with impact 
has been inevitable. The edge factor is a valuable tool for this very reason. By providing an 
approach that can be used to measure the novelty of scientific work of a nation, a journal, an 
institution, or even an individual scientist, the edge factor allows university administrators and 
funding agencies to re-structure their reward systems so that scientists are rewarded based on not 
just the impact of their work but also the novelty of their work. When scientists are rewarded 
based on both the impact and novelty of their work, more scientists can be expected to pursue 
novel research paths, leading to healthier, less stagnant science.    
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Figure 1. Overall Scientific Frontier Position by Location. Edge factors are calculated using text 
analysis and data on biomedical research papers published during 2015-2016. Scatter points are 
colored to indicate edge factors that are well above average (red), about average (grey), and well 
below average (blue). An edge factor above 100 indicates an above average tendency for work 
that builds on relatively new ideas (a contribution is considered novel if it is in the top 5% by the 
age of the newest idea it builds upon; the comparison group for each contribution is all other 
papers published in the same year and linked to the same (idea category, research area) pair).  
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Figure 2. Change in Scientific Frontier Position by Location from 1990s to present. Edge factors 
are calculated using text analysis and data on biomedical research papers published during 1990-
1999 and 2015-2016. Smaller scatter points indicate the edge factors for 1990s, larger points for 
2015-6. Red (blue) arrows indicate edge factors that increased (decreased) from 1990s to 2015-
2016. An edge factor above 100 indicates an above average tendency for work that builds on 
relatively new ideas (a contribution is considered novel if it is in the top 5% by the age of the 
newest idea it builds upon; the comparison group for each contribution is all other papers published 
in the same year and linked to the same (idea category, research area) pair).  
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Table 1. Edge Factors by Idea Category Type and by Research Area Type.
 
(1a) (1b) (1c) (2a) (2b) (2c) (2d) (3a) (3b) (3c)
Location Number of 
Contributions
2015-6 Clinical 
and 
Anatomy
Drugs 
and 
Chemi-
cals
Basic 
Science 
and 
Research 
Tools
Miscel-
laneous
Applied Basic 
Science
Other 
(Both 
Applied 
and Basic 
Science)
UNITED STATES 2853661 108 105 121 110 105 106 108 108
SOUTH KOREA 374227 107 111 103 105 105 103 109 106
SINGAPORE 52541 105 109 106 115 108 108 110 112
TAIWAN 177229 104 99 100 105 105 100 101 107
IRELAND 39495 103 107 88 108 98 99 101 108
BELGIUM 95644 102 109 120 99 98 103 106 102
ITALY 384029 102 105 117 94 101 99 103 103
CHINA 1734035 101 95 88 113 101 102 100 103
CANADA 375846 101 99 94 102 105 101 99 105
JAPAN 554589 100 104 106 103 92 94 104 101
UNITED KINGDOM 494917 100 100 105 100 100 98 102 100
NETHERLANDS 233631 100 106 87 100 97 95 103 100
GERMANY 539888 100 95 112 104 97 96 102 100
SWITZERLAND 123779 100 97 118 105 93 94 102 102
SAUDI ARABIA 34855 99 96 84 91 96 90 92 98
FINLAND 59534 99 96 78 106 96 89 99 102
NORWAY 63699 98 99 88 103 98 97 97 104
SOUTH AFRICA 43179 98 107 81 76 98 100 92 89
SPAIN 278504 98 98 96 96 99 92 99 101
CZECH REPUBLIC 44024 97 97 86 95 92 95 97 89
AUSTRALIA 320955 97 99 94 95 97 96 95 100
SWEDEN 138949 96 94 102 97 93 91 98 96
AUSTRIA 65039 96 94 103 100 94 91 100 96
DENMARK 105066 95 98 91 96 96 92 95 101
FRANCE 305065 95 96 101 95 93 91 97 95
POLAND 113074 93 95 85 83 91 95 89 84
THAILAND 40080 93 95 79 73 94 91 81 92
HUNGARY 28574 92 84 94 93 85 88 89 87
ISRAEL 76781 92 96 78 95 90 88 95 94
OTHER EUROPE 107712 90 91 79 82 84 85 83 88
NEW ZEALAND 38946 90 90 111 88 93 92 95 90
TURKEY 157825 90 101 79 69 93 87 85 91
RUSSIA 51759 89 77 91 93 85 86 85 84
CHILE 23794 89 98 76 75 91 95 86 83
GREECE 46646 89 95 88 76 86 86 87 86
MALAYSIA 37997 87 87 64 81 90 87 83 83
PORTUGAL 65523 86 92 84 85 93 92 91 85
OTHER ASIA 60973 86 87 84 73 81 85 78 82
INDIA 291215 83 83 70 73 95 86 83 80
BRAZIL 274896 83 83 74 71 96 83 82 82
PAKISTAN 27511 83 78 93 74 80 81 79 77
MEXICO 54997 81 81 72 72 86 82 76 80
IRAN 121035 78 87 62 68 82 77 76 81
OTHER AMERICAS 30787 77 82 76 64 96 87 78 78
ARGENTINA 40775 77 85 76 69 86 82 79 78
EGYPT 48649 75 85 75 58 81 76 75 74
OTHER AFRICA 90041 70 87 57 55 73 76 68 72
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Notes to Table 1:  
 
All numbers in columns 1b and 1c are calculated based on papers published during 2015-2016. Numbers in columns 
2a-d and columns 3a-3c are also calculated based on papers published during 2015-2016 for all countries for which 
the number of contributions reported in column 1c is at least 200000. For countries that fall below this threshold, the 
numbers in columns 2a-d and columns 3a-3c are calculated based on papers published during 2010-2016 (in order to 
decrease the variability of the edge factors reported in these columns).  
 
Column 1a: Location. 
 
Column 1b: Number of contributions based on which the edge factor in column (1c) is calculated. A contribution is 
defined as a link from a paper to an (idea category, research area) pair. A paper can link to multiple (idea category, 
research area) pairs because a paper can mention UMLS terms from multiple idea categories, and because a UMLS 
term can be linked to multiple idea categories, and because a paper may be linked to multiple research areas.  
 
Column 1c: Edge factor for the baseline specification. 
 
Columns 2a-d: Edge factors for each of the four idea category groups “Clinical and Anatomy”, “Drugs and 
Chemicals”, “Basic Science and Research Tools”, and “Miscellaneous”. See Table S1 for which idea categories (as 
represented by UMLS categories for UMLS terms) are included in each idea category group.  
 
Columns 3a-c: Edge factors for each of the three types of research areas: “Applied”, “Basic Science”, and Other 
(Both Applied and Basic Science)”. See Table S1 for which research areas (represented by journal categories) are 
included in each of these three research area types. 
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Figure S1. Number of papers per year in the MEDLINE database. Even after limiting the 
analysis to regular research papers (thereby excluding news items, editorials, etc.), the database 
includes mullions of papers for even the earlier decades allowing us to obtain an informative 
estimate of when each idea was new to the biomedical literature.  
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Figure S2. Share of papers matched to a location. The match rate is reasonably high even for 
1990s. The decrease in the rate of matched papers in recent years is due to the fact that for those 
years some of the affiliation strings in MEDLINE include the affiliation string for multiple 
authors. The form of such entries makes it more difficult to match those papers to a country. 
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Figure S3. Share of papers by location. The U.S., U.K., Japan, Germany, and Italy have been 
among near the top in terms of extent of biomedical research production throughout the sample 
period, while China, India, and South Korea have become big centers of biomedical research 
production during the last two decades. 
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Figure S4. Distribution of the Cohort of Contributions. The number of contributions with cohort 
“1975” is disproportionately high because the comprehensive coverage of article abstracts in 
MEDLINE begins in 1975 (and thus a disproportionate number of terms are assigned cohort 
1975 by our approach). 
  
	 6	
 
 
 
Figure S5. Share of Novel Contributions by Cohort. When the top 5% cutoff is used, 
then for all post-2004 cohorts the majority of contributions with that cohort are deemed novel by 
our approach, and for all pre-2004 cohorts at most a minority of contributions are deemed novel 
by our approach. Contributions with a very early cohort are never novel and contributions with 
the latest possible cohort (“2016”) are all novel. Contributions with a cohort between these 
extremes are sometimes novel and other times not. This is because novelty is calculated by 
comparing the vintage of a contribution to the vintage of other contributions linked to the same 
(idea category, research area) pair. Hence, the cutoff cohort for novel contributions varies across 
(idea category, research area) pairs.   
 
 
 
 
  
Table S1. Number of Links from Papers to Each Research Area.
Research Area (Journal Category)         Links   Research Area Group
Medicine                                 669881  Other (Both Applied and Basic Science)
Science                                  599469  Basic Science
Neoplasms                                524947  Other (Both Applied and Basic Science)
Biochemistry                             499331  Basic Science
Molecular Biology                        470936  Basic Science
Neurology                                404341  Other (Both Applied and Basic Science)
Chemistry                                381274  Basic Science
Pharmacology                             283555  Other (Both Applied and Basic Science)
Biology                                  264824  Basic Science
Cell Biology                             256341  Basic Science
General Surgery                          247670  Applied
Environmental Health                     233734  Other (Both Applied and Basic Science)
Allergy and Immunology                   216658  Basic Science
Microbiology                             196761  Basic Science
Cardiology                               192365  Applied
Biomedical Engineering                   191269  Other (Both Applied and Basic Science)
Biotechnology                            184539  Basic Science
Biophysics                               174613  Basic Science
Vascular Diseases                        174607  Other (Both Applied and Basic Science)
Physiology                               172288  Other (Both Applied and Basic Science)
Public Health                            163958  Applied
Pediatrics                               163047  Applied
Nutritional Sciences                     161807  Other (Both Applied and Basic Science)
Toxicology                               158233  Other (Both Applied and Basic Science)
Psychiatry                               155919  Applied
Gastroenterology                         129905  Other (Both Applied and Basic Science)
Endocrinology                            127616  Other (Both Applied and Basic Science)
Psychology                               122978  Applied
Genetics                                 121180  Basic Science
Nursing                                  116035  Applied
Ophthalmology                            112186  Other (Both Applied and Basic Science)
Chemistry Techniques, Analytical         107968  Other (Both Applied and Basic Science)
Pulmonary Medicine                       103534  Applied
Orthopedics                              102817  Applied
Diagnostic Imaging                       101475  Applied
Dentistry                                101252  Applied
Pathology                                 99477  Other (Both Applied and Basic Science)
Metabolism                                98272  Other (Both Applied and Basic Science)
Communicable Diseases                     96646  Other (Both Applied and Basic Science)
Therapeutics                              95906  Other (Both Applied and Basic Science)
Veterinary Medicine                       95394  Other (Both Applied and Basic Science)
Radiology                                 95332  Applied
Behavioral Sciences                       91608  Applied
Brain                                     90578  Other (Both Applied and Basic Science)
Nanotechnology                            87781  Basic Science
Hematology                                87705  Other (Both Applied and Basic Science)
Geriatrics                                82363  Applied
Botany                                    81144  Other (Both Applied and Basic Science)
Physics                                   80223  Other (Both Applied and Basic Science)
Gynecology                                76024  Applied
Genetics, Medical                         75252  Other (Both Applied and Basic Science)
Health Services                           74519  Applied
Psychophysiology                          70549  Applied
Obstetrics                                69653  Applied
Virology                                  68388  Basic Science
Technology                                66620  Other (Both Applied and Basic Science)
Urology                                   65771  Applied
Reproductive Medicine                     63949  Other (Both Applied and Basic Science)
Drug Therapy                              63105  Other (Both Applied and Basic Science)
Zoology                                   62592  Other (Both Applied and Basic Science)
Medical Informatics                       61238  Applied
Transplantation                           59013  Other (Both Applied and Basic Science)
Health Services Research                  53889  Applied
Traumatology                              53820  Applied
Nephrology                                51255  Other (Both Applied and Basic Science)
Physical and Rehabilitation Medicine      50756  Applied
Rheumatology                              50730  Other (Both Applied and Basic Science)
Dermatology                               49397  Other (Both Applied and Basic Science)
Epidemiology                              48742  Applied
Social Sciences                           47935  Applied
Sports Medicine                           45323  Applied
Tropical Medicine                         44027  Other (Both Applied and Basic Science)
Otolaryngology                            43871  Applied
Computational Biology                     43373  Basic Science
Radiotherapy                              42859  Applied
Parasitology                              40296  Other (Both Applied and Basic Science)
Substance-Related Disorders               39722  Applied
Complementary Therapies                   39646  Other (Both Applied and Basic Science)
Anti-Infective Agents                     38006  Basic Science
Neurosurgery                              37052  Applied
Acquired Immunodeficiency Syndrome        34489  Other (Both Applied and Basic Science)
Nuclear Medicine                          33864  Other (Both Applied and Basic Science)
Education                                 33318  Applied
Emergency Medicine                        32612  Applied
Critical Care                             32054  Applied
Anesthesiology                            31729  Applied
Perinatology                              31395  Applied
Clinical Laboratory Techniques            30107  Other (Both Applied and Basic Science)
Embryology                                29322  Other (Both Applied and Basic Science)
Pharmacy                                  28546  Other (Both Applied and Basic Science)
Palliative Care                           27801  Applied
Psychopharmacology                        27246  Applied
Internal Medicine                         24728  Applied
Occupational Medicine                     20677  Applied
Statistics as Topic                       20049  Applied
Antineoplastic Agents                     19027  Other (Both Applied and Basic Science)
Primary Health Care                       18607  Applied
Jurisprudence                             17346  Other (Both Applied and Basic Science)
Histology                                 15443  Basic Science
Hospitals                                 14323  Other (Both Applied and Basic Science)
Audiology                                 13697  Applied
Sexually Transmitted Diseases             11994  Other (Both Applied and Basic Science)
Anatomy                                   11926  Other (Both Applied and Basic Science)
Ethics                                    11039  Applied
Bacteriology                              10395  Basic Science
Speech-Language Pathology                 10150  Applied
Women's Health                             9976  Applied
Histocytochemistry                         8834  Basic Science
Chemistry, Clinical                        8529  Other (Both Applied and Basic Science)
Forensic Sciences                          8528  Other (Both Applied and Basic Science)
Military Medicine                          7359  Applied
Orthodontics                               5106  Applied
Anthropology                               4340  Applied
Laboratory Animal Science                  3784  Other (Both Applied and Basic Science)
Vital Statistics                           3672  Other (Both Applied and Basic Science)
History of Medicine                        3580  Applied
Disaster Medicine                          3491  Applied
Teratology                                 1938  Other (Both Applied and Basic Science)
Podiatry                                   1671  Applied
Aerospace Medicine                         1591  Applied
Family Planning Services                   1396  Applied
Chiropractic                                648  Applied
Osteopathic Medicine                        385  Applied
Library Science                             226  Applied
Table S2. Number of Links from Papers to Each Idea Category.
Idea Category                                 Links   Idea Category Group
Finding                                       606119  Clinical and Anatomy
Amino Acid, Peptide, or Protein               529613  Basic Science and Research Tools
Pharmacologic Substance                       527933  Drugs and Chemicals
Quantitative Concept                          495874  Miscellaneous
Intellectual Product                          485671  Miscellaneous
Laboratory Procedure                          478481  Clinical and Anatomy
Gene or Genome                                470078  Basic Science and Research Tools
Research Activity                             380742  Basic Science and Research Tools
Therapeutic or Preventive Procedure           374185  Clinical and Anatomy
Disease or Syndrome                           353348  Clinical and Anatomy
Molecular Function                            303528  Basic Science and Research Tools
Functional Concept                            289601  Miscellaneous
Clinical Attribute                            282872  Clinical and Anatomy
Diagnostic Procedure                          261596  Clinical and Anatomy
Manufactured Object                           244287  Miscellaneous
Qualitative Concept                           239603  Miscellaneous
Cell Function                                 231778  Basic Science and Research Tools
Genetic Function                              202810  Basic Science and Research Tools
Organic Chemical                              200841  Drugs and Chemicals
Mental Process                                184553  Clinical and Anatomy
Health Care Activity                          182871  Clinical and Anatomy
Cell                                          172497  Basic Science and Research Tools
Idea or Concept                               166488  Miscellaneous
Nucleic Acid, Nucleoside, or Nucleotide       155993  Basic Science and Research Tools
Spatial Concept                               140830  Miscellaneous
Molecular Biology Research Technique          135534  Basic Science and Research Tools
Neoplastic Process                            125951  Clinical and Anatomy
Body Part, Organ, or Organ Component          121709  Clinical and Anatomy
Temporal Concept                              121231  Miscellaneous
Medical Device                                119522  Clinical and Anatomy
Biomedical Occupation or Discipline           117883  Miscellaneous
Cell Component                                113613  Basic Science and Research Tools
Population Group                              112704  Miscellaneous
Pathologic Function                           108290  Clinical and Anatomy
Professional or Occupational Group            106552  Miscellaneous
Activity                                       97839  Miscellaneous
Mental or Behavioral Dysfunction               88458  Clinical and Anatomy
Indicator, Reagent, or Diagnostic Aid          84232  Clinical and Anatomy
Organ or Tissue Function                       80670  Clinical and Anatomy
Plant                                          79846  Miscellaneous
Natural Phenomenon or Process                  78537  Basic Science and Research Tools
Educational Activity                           76874  Clinical and Anatomy
Biologically Active Substance                  70188  Drugs and Chemicals
Sign or Symptom                                69915  Clinical and Anatomy
Eukaryote                                      69229  Basic Science and Research Tools
Bacterium                                      68427  Basic Science and Research Tools
Cell or Molecular Dysfunction                  65978  Basic Science and Research Tools
Hazardous or Poisonous Substance               62697  Drugs and Chemicals
Laboratory or Test Result                      61984  Clinical and Anatomy
Injury or Poisoning                            61553  Clinical and Anatomy
Conceptual Entity                              61528  Miscellaneous
Social Behavior                                60906  Miscellaneous
Mammal                                         57221  Miscellaneous
Organism Function                              55354  Basic Science and Research Tools
Biomedical or Dental Material                  55315  Drugs and Chemicals
Organism Attribute                             54953  Miscellaneous
Virus                                          51368  Basic Science and Research Tools
Occupation or Discipline                       50613  Miscellaneous
Individual Behavior                            48054  Miscellaneous
Body Location or Region                        47276  Clinical and Anatomy
Health Care Related Organization               46763  Miscellaneous
Classification                                 46324  Miscellaneous
Nucleotide Sequence                            45571  Basic Science and Research Tools
Occupational Activity                          45153  Miscellaneous
Phenomenon or Process                          44693  Basic Science and Research Tools
Element, Ion, or Isotope                       43951  Basic Science and Research Tools
Physiologic Function                           43616  Clinical and Anatomy
Geographic Area                                40627  Miscellaneous
Experimental Model of Disease                  38736  Clinical and Anatomy
Amino Acid Sequence                            38461  Basic Science and Research Tools
Machine Activity                               36253  Miscellaneous
Tissue                                         36151  Basic Science and Research Tools
Immunologic Factor                             35682  Basic Science and Research Tools
Organism                                       32501  Basic Science and Research Tools
Inorganic Chemical                             27299  Drugs and Chemicals
Animal                                         25586  Miscellaneous
Food                                           24315  Miscellaneous
Age Group                                      23986  Miscellaneous
Daily or Recreational Activity                 23540  Miscellaneous
Chemical Viewed Functionally                   21956  Drugs and Chemicals
Fish                                           21900  Miscellaneous
Family Group                                   21721  Miscellaneous
Biologic Function                              21506  Basic Science and Research Tools
Substance                                      20164  Basic Science and Research Tools
Group                                          19705  Miscellaneous
Body Space or Junction                         18744  Clinical and Anatomy
Congenital Abnormality                         18684  Clinical and Anatomy
Clinical Drug                                  17971  Drugs and Chemicals
Fungus                                         17966  Basic Science and Research Tools
Research Device                                17100  Basic Science and Research Tools
Governmental or Regulatory Activity            16215  Miscellaneous
Body Substance                                 16146  Basic Science and Research Tools
Chemical Viewed Structurally                   15715  Drugs and Chemicals
Chemical                                       14247  Drugs and Chemicals
Patient or Disabled Group                      13280  Miscellaneous
Organization                                   11961  Miscellaneous
Receptor                                       11335  Basic Science and Research Tools
Human-caused Phenomenon or Process             10689  Basic Science and Research Tools
Bird                                            9043  Miscellaneous
Acquired Abnormality                            9040  Clinical and Anatomy
Regulation or Law                               8969  Miscellaneous
Anatomical Abnormality                          8896  Clinical and Anatomy
Environmental Effect of Humans                  8268  Miscellaneous
Body System                                     7871  Clinical and Anatomy
Group Attribute                                 7303  Miscellaneous
Behavior                                        6400  Miscellaneous
Embryonic Structure                             5498  Basic Science and Research Tools
Professional Society                            4272  Miscellaneous
Event                                           3825  Miscellaneous
Reptile                                         3289  Miscellaneous
Hormone                                         2983  Drugs and Chemicals
Self-help or Relief Organization                2927  Miscellaneous
Archaeon                                        2620  Basic Science and Research Tools
Vitamin                                         2514  Drugs and Chemicals
Language                                        2422  Miscellaneous
Anatomical Structure                            2293  Clinical and Anatomy
Physical Object                                 2017  Miscellaneous
Amphibian                                       1918  Miscellaneous
Molecular Sequence                              1453  Basic Science and Research Tools
Antibiotic                                       861  Drugs and Chemicals
Drug Delivery Device                             790  Drugs and Chemicals
Fully Formed Anatomical Structure                104  Clinical and Anatomy
Entity                                            78  Miscellaneous
Human                                             44  Miscellaneous
Vertebrate                                        15  Miscellaneous
Table S3: Examples of UMLS Terms.
(1)   (2)         (3)      (4)        (5)                                                 (6)          (7) 
CLINICAL AND ANATOMY (1st of 4 idea category groups)
2010s  1          780      1.98%      granulomatosis with polyangiitis                    2011 (1949)  Disease or Syndrome
2010s  2          698      3.76%      H7N9                                                2010 (1949)  Disease or Syndrome
2010s  3          388      4.75%      fecal microbiota transplantation                    2011 (2001)  Therapeutic or Preventive Procedure
2010s  4          365      5.68%      middle east respiratory syndrome                    2013 (1974)  Disease or Syndrome
2010s  5          279      6.39%      eosinophilic granulomatosis with polyangiitis       2012 (2012)  Disease or Syndrome
2010s  6          182      6.85%      ecigarette user                                     2011 (2010)  Finding
A UMLS term that is linked to multiple UMLS categories is treated as multiple separate observations; each such link represents one observation. All 
(UMLS term, UMLS category) pairs are first ranked based on the number of times the UMLS term is the newest term in a paper among all terms that 
belong to the same UMLS category. 
We present 4 separate lists, one for each of the following four groups of idea categories that we use in the paper (Table S2 shows how the 127 UMLS 
categories map into these 4 category groups): “Clinical and Anatomy”, “Drugs and Chemicals”, “Basic Science and Research Tools”, and “Miscellaneous” 
The rankings are constructed separately for each of these 4 idea category groups and for each decade, with the decade determined based on the cohort year 
of the UMLS term. The cohort year of a UMLS term is the year the term is first mentioned in the MEDLINE database. For each UMLS term the table also 
lists the earliest cohort of any of the term’s synonyms that appear in the UMLS metathesaurus. 
For each decade we only present the top 25 UMLS terms. The analysis in the paper is based on all UMLS terms, not only the UMLS terms presented here. 
The focus on on a narrow set of popular UMLS terms here is for expositional convenience only. 
Explanations for the columns: 
Column (1): Decade of cohort; calculated based on the first number in column (6). 
Column (2): Rank within decade of cohort; calculated based on column (3) and the first number in column (6). 
Column (3): Number of times the UMLS term appears in a paper and is the newest term in the paper from that idea category. Calculated based on papers 
published during 2010-2016. 
Column (4): Cumulative share of earliest mentions, calculated based on column (3) separately for each decade of cohort.. 
Column (5): The UMLS term. 
Column (6): Cohort of term, set as the earliest year the term is mentioned in MEDLINE. The number in parenthesis is the earliest cohort of any synonym of 
the term (including the term itself). 
Column (7): The UMLS category of the term; in our analysis this represents the idea category of the term. 
The UMLS term lists for the 4 idea category groups appear in this order below: “Clinical and Anatomy”, “Drugs and Chemicals”, “Basic Science and 
Research Tools”, and “Miscellaneous”.
2010s  7          176      7.30%      H7N9 influenza                                      2012 (2012)  Disease or Syndrome
2010s  8          150      7.68%      patientderived xenograft model                      2010 (1989)  Experimental Model of Disease
2010s  9          150      8.06%      vascularized composite allotransplantation          2011 (1991)  Therapeutic or Preventive Procedure
2010s  10         146      8.43%      auditory neuropathy spectrum disorder               2010 (1996)  Disease or Syndrome
2010s  11         143      8.80%      hoarding disorder                                   2010 (2010)  Mental or Behavioral Dysfunction
2010s  12         132      9.13%      prostate health index                               2010 (1949)  Laboratory Procedure
2010s  13         125      9.45%      severe fever with thrombocytopenia syndrome         2011 (2011)  Disease or Syndrome
2010s  14         117      9.75%      tedizolid                                           2011 (2011)  Clinical Attribute
2010s  15         114      10.0%      C3 glomerulopathy                                   2010 (2010)  Disease or Syndrome
2010s  16         112      10.3%      severe fever with thrombocytopenia syndrome virus   2012 (2011)  Disease or Syndrome
2010s  17         108      10.6%      primary biliary cholangitis                         2015 (1949)  Disease or Syndrome
2010s  18         107      10.8%      florbetapir                                         2010 (2010)  Indicator, Reagent, or Diagnostic Aid
2010s  19         102      11.1%      fusion biopsy                                       2012 (2011)  Diagnostic Procedure
2010s  20         92       11.3%      mixed adenoneuroendocrine carcinoma                 2011 (1963)  Neoplastic Process
2000s  1          4562     1.88%      STEMI                                               2000 (2000)  Finding
2000s  2          4516     3.75%      STEMI                                               2000 (1994)  Disease or Syndrome
2000s  3          3811     5.33%      everolimus                                          2000 (2000)  Laboratory Procedure
2000s  4          3292     6.69%      creactive protein hs                                2000 (2000)  Laboratory Procedure
2000s  5          3055     7.95%      castrationresistant prostate cancer                 2004 (1983)  Neoplastic Process
2000s  6          2977     9.18%      cardiac resynchronization therapy                   2000 (2000)  Therapeutic or Preventive Procedure
2000s  7          2928     10.3%      multidetector computed tomography                   2000 (1992)  Diagnostic Procedure
2000s  8          2888     11.5%      transcatheter aortic valve implantation             2005 (1990)  Therapeutic or Preventive Procedure
2000s  9          2485     12.6%      positron emission tomography computed tomography    2002 (1991)  Diagnostic Procedure
2000s  10         2313     13.5%      triplenegative breast cancer                        2006 (2006)  Finding
2000s  11         2131     14.4%      endoscopic submucosal dissection                    2004 (2004)  Therapeutic or Preventive Procedure
2000s  12         2041     15.3%      triplenegative breast cancer                        2006 (2006)  Neoplastic Process
2000s  13         1985     16.1%      CXCL10                                              2001 (1983)  Laboratory Procedure
2000s  14         1968     16.9%      transcranial direct current stimulation             2000 (1987)  Therapeutic or Preventive Procedure
2000s  15         1618     17.6%      transcatheter aortic valve replacement              2006 (1990)  Therapeutic or Preventive Procedure
2000s  16         1540     18.2%      transcriptome sequencing                            2007 (2007)  Laboratory Procedure
2000s  17         1455     18.8%      tigecycline                                         2002 (2002)  Clinical Attribute
2000s  18         1443     19.4%      MELD score                                          2001 (2001)  Clinical Attribute
2000s  19         1434     20.0%      MELD score                                          2001 (2001)  Laboratory Procedure
2000s  20         1355     20.5%      takotsubo cardiomyopathy                            2000 (1976)  Disease or Syndrome
1990s  1          16494    2.08%      fmri                                                1994 (1988)  Diagnostic Procedure
1990s  2          16180    4.12%      optical coherence tomography                        1991 (1991)  Diagnostic Procedure
1990s  3          12851    5.75%      percutaneous coronary intervention                  1991 (1991)  Therapeutic or Preventive Procedure
1990s  4          9244     6.92%      adiponectin                                         1999 (1999)  Laboratory Procedure
1990s  5          8538     7.99%      microarray analysis                                 1998 (1989)  Laboratory Procedure
1990s  6          7631     8.96%      chromatin immunoprecipitation                       1998 (1949)  Laboratory Procedure
1990s  7          6933     9.83%      MMP9                                                1991 (1991)  Laboratory Procedure
1990s  8          6657     10.6%      pyrosequencing                                      1998 (1998)  Laboratory Procedure
1990s  9          6447     11.4%      autism spectrum disorder                            1992 (1992)  Finding
1990s  10         6188     12.2%      diffusion tensor imaging                            1994 (1994)  Diagnostic Procedure
1990s  11         5886     13.0%      NAFLD                                               1998 (1977)  Disease or Syndrome
1990s  12         5528     13.7%      autism spectrum disorder                            1992 (1981)  Mental or Behavioral Dysfunction
1990s  13         5398     14.4%      gene expression profiling                           1998 (1989)  Laboratory Procedure
1990s  14         4795     15.0%      autism spectrum disorders                           1992 (1982)  Mental or Behavioral Dysfunction
1990s  15         4314     15.5%      tacrolimus                                          1992 (1992)  Laboratory Procedure
1990s  16         4295     16.0%      BRCA1                                               1993 (1993)  Laboratory Procedure
1990s  17         3722     16.5%      ghrelin                                             1999 (1989)  Laboratory Procedure
1990s  18         3535     17.0%      highly active antiretroviral therapy                1996 (1970)  Therapeutic or Preventive Procedure
1990s  19         3534     17.4%      microcomputed tomography                            1990 (1975)  Diagnostic Procedure
1990s  20         3138     17.8%      statin therapy                                      1993 (1993)  Therapeutic or Preventive Procedure
1980s  1          30408    1.53%      polymerase chain reaction                           1986 (1986)  Laboratory Procedure
1980s  2          19973    2.53%      western blot                                        1981 (1981)  Laboratory Procedure
1980s  3          18078    3.45%      primary endpoint                                    1980 (1980)  Indicator, Reagent, or Diagnostic Aid
1980s  4          17719    4.34%      HIV1                                                1986 (1986)  Laboratory or Test Result
1980s  5          17599    5.23%      VEGF                                                1987 (1982)  Laboratory Procedure
1980s  6          17530    6.11%      vascular endothelial growth factor                  1982 (1982)  Therapeutic or Preventive Procedure
1980s  7          15337    6.88%      tissue engineering                                  1984 (1984)  Therapeutic or Preventive Procedure
1980s  8          15075    7.64%      NSCLC                                               1981 (1976)  Neoplastic Process
1980s  9          14097    8.35%      western blot analysis                               1982 (1981)  Laboratory Procedure
1980s  10         13523    9.04%      HIV infection                                       1986 (1986)  Clinical Attribute
1980s  11         12977    9.69%      neuroimaging                                        1982 (1982)  Diagnostic Procedure
1980s  12         12828    10.3%      antiretroviral therapy                              1985 (1985)  Therapeutic or Preventive Procedure
1980s  13         11657    10.9%      EGFR                                                1980 (1977)  Laboratory Procedure
1980s  14         11549    11.5%      atomic force microscopy                             1988 (1976)  Laboratory Procedure
1980s  15         11367    12.0%      LCMS                                                1982 (1970)  Laboratory Procedure
1980s  16         10204    12.5%      HIV infection                                       1986 (1983)  Disease or Syndrome
1980s  17         9567     13.0%      human immunodeficiency virus                        1986 (1983)  Disease or Syndrome
1980s  18         9546     13.5%      confocal microscopy                                 1981 (1981)  Laboratory Procedure
1980s  19         8799     14.0%      interleukin6                                        1987 (1987)  Laboratory Procedure
1980s  20         8322     14.4%      PTSD                                                1982 (1949)  Mental or Behavioral Dysfunction
1970s  1          71568    2.12%      biomarkers                                          1973 (1949)  Clinical Attribute
1970s  2          44237    3.43%      magnetic resonance imaging                          1978 (1949)  Diagnostic Procedure
1970s  3          40954    4.64%      body mass index                                     1975 (1975)  Diagnostic Procedure
1970s  4          35912    5.71%      biomarker                                           1973 (1949)  Clinical Attribute
1970s  5          34725    6.74%      body mass index                                     1975 (1970)  Clinical Attribute
1970s  6          34105    7.75%      body mass index                                     1975 (1975)  Finding
1970s  7          27597    8.56%      body mass index BMI                                 1978 (1978)  Clinical Attribute
1970s  8          23495    9.26%      flow cytometry                                      1977 (1971)  Laboratory Procedure
1970s  9          18772    9.82%      treatment options                                   1971 (1950)  Therapeutic or Preventive Procedure
1970s  10         17892    10.3%      T cells                                             1970 (1970)  Laboratory Procedure
1970s  11         17877    10.8%      HPLC                                                1973 (1969)  Laboratory Procedure
1970s  12         17627    11.4%      risk assessment                                     1973 (1973)  Health Care Activity
1970s  13         15331    11.8%      ELISA                                               1971 (1971)  Laboratory Procedure
1970s  14         13416    12.2%      CD8                                                 1979 (1979)  Laboratory Procedure
1970s  15         12428    12.6%      interventional                                      1971 (1971)  Diagnostic Procedure
1970s  16         11965    12.9%      neurodegeneration                                   1976 (1976)  Finding
1970s  17         11292    13.3%      cancer progression                                  1979 (1979)  Pathologic Function
1970s  18         11170    13.6%      neurodegenerative diseases                          1979 (1965)  Disease or Syndrome
1970s  19         10573    13.9%      poor outcome                                        1975 (1975)  Finding
1970s  20         10449    14.2%      working memory                                      1977 (1949)  Mental Process
1960s  1          59518    2.01%      immunohistochemistry                                1964 (1964)  Diagnostic Procedure
1960s  2          48580    3.65%      mouse model                                         1965 (1965)  Experimental Model of Disease
1960s  3          38862    4.96%      sequencing                                          1962 (1962)  Laboratory Procedure
1960s  4          24939    5.81%      scanning electron microscopy                        1963 (1963)  Diagnostic Procedure
1960s  5          24752    6.64%      colorectal cancer                                   1962 (1962)  Finding
1960s  6          23258    7.43%      colorectal cancer                                   1962 (1949)  Neoplastic Process
1960s  7          19812    8.10%      ethnicity                                           1966 (1966)  Clinical Attribute
1960s  8          15572    8.62%      ethnicity                                           1966 (1966)  Finding
1960s  9          14815    9.13%      crosstalk                                           1966 (1966)  Injury or Poisoning
1960s  10         13656    9.59%      scanning electron microscopy                        1963 (1963)  Laboratory Procedure
1960s  11         13069    10.0%      COPD                                                1967 (1949)  Disease or Syndrome
1960s  12         12966    10.4%      ischemic stroke                                     1963 (1963)  Finding
1960s  13         12852    10.9%      coherent                                            1961 (1961)  Finding
1960s  14         12795    11.3%      immunosuppression                                   1964 (1964)  Pathologic Function
1960s  15         12684    11.7%      transmission electron microscopy                    1964 (1949)  Laboratory Procedure
1960s  16         12680    12.1%      chart review                                        1966 (1957)  Health Care Activity
1960s  17         12659    12.6%      ischemic stroke                                     1963 (1962)  Disease or Syndrome
1960s  18         12121    13.0%      high risk of                                        1961 (1955)  Finding
1960s  19         11154    13.4%      NMR spectroscopy                                    1965 (1961)  Diagnostic Procedure
1960s  20         11087    13.7%      inflammatory bowel disease                          1964 (1964)  Finding
1950s  1          222028   4.98%      strategies                                          1955 (1955)  Educational Activity
1950s  2          213336   9.77%      strategies                                          1955 (1949)  Mental Process
1950s  3          75034    11.4%      quality of life                                     1959 (1959)  Sign or Symptom
1950s  4          69350    13.0%      risk factors                                        1959 (1959)  Finding
1950s  5          58653    14.3%      encoding                                            1956 (1953)  Mental Process
1950s  6          56850    15.6%      documented                                          1950 (1950)  Health Care Activity
1950s  7          45073    16.6%      quality of life                                     1959 (1959)  Finding
1950s  8          25692    17.1%      options                                             1950 (1950)  Therapeutic or Preventive Procedure
1950s  9          24733    17.7%      risk factor                                         1959 (1959)  Finding
1950s  10         24543    18.3%      pharmacokinetics                                    1955 (1949)  Physiologic Function
1950s  11         23834    18.8%      immune responses                                    1950 (1949)  Organ or Tissue Function
1950s  12         23790    19.3%      immunohistochemical                                 1956 (1956)  Laboratory Procedure
1950s  13         23673    19.9%      encoded                                             1953 (1953)  Mental Process
1950s  14         22955    20.4%      hepatocellular carcinoma                            1951 (1949)  Neoplastic Process
1950s  15         22021    20.9%      computed tomography                                 1956 (1949)  Diagnostic Procedure
1950s  16         21976    21.4%      high risk                                           1955 (1955)  Health Care Activity
1950s  17         21905    21.9%      hepatocellular carcinoma                            1951 (1951)  Finding
1950s  18         20433    22.3%      triggers                                            1955 (1949)  Clinical Attribute
1950s  19         19918    22.8%      animal model                                        1954 (1954)  Experimental Model of Disease
1950s  20         19524    23.2%      laparoscopic                                        1950 (1949)  Diagnostic Procedure
DRUGS AND CHEMICALS (2nd of 4 idea category groups)
2010s  1          856      1.29%      crizotinib                                          2010 (2010)  Pharmacologic Substance
2010s  2          851      2.57%      vemurafenib                                         2011 (2011)  Pharmacologic Substance
2010s  3          686      3.61%      enzalutamide                                        2012 (2012)  Pharmacologic Substance
2010s  4          465      4.31%      ibrutinib                                           2012 (2012)  Pharmacologic Substance
2010s  5          457      5.00%      ruxolitinib                                         2010 (2010)  Pharmacologic Substance
2010s  6          449      5.68%      nivolumab                                           2013 (2013)  Pharmacologic Substance
2010s  7          438      6.34%      afatinib                                            2011 (2011)  Pharmacologic Substance
2010s  8          433      7.00%      pembrolizumab                                       2014 (2013)  Pharmacologic Substance
2010s  9          410      7.61%      sofosbuvir                                          2013 (2013)  Pharmacologic Substance
2010s  10         384      8.19%      dabrafenib                                          2012 (2012)  Pharmacologic Substance
2010s  11         336      8.70%      simeprevir                                          2013 (2008)  Pharmacologic Substance
2010s  12         329      9.20%      tofacitinib                                         2010 (2008)  Pharmacologic Substance
2010s  13         326      9.69%      regorafenib                                         2011 (2011)  Pharmacologic Substance
2010s  14         318      10.1%      brentuximab vedotin                                 2010 (2003)  Pharmacologic Substance
2010s  15         311      10.6%      dolutegravir                                        2011 (2011)  Pharmacologic Substance
2010s  16         308      11.1%      empagliflozin                                       2012 (2012)  Pharmacologic Substance
2010s  17         268      11.5%      canagliflozin                                       2010 (2010)  Pharmacologic Substance
2010s  18         256      11.9%      vismodegib                                          2010 (2010)  Pharmacologic Substance
2010s  19         251      12.2%      ponatinib                                           2011 (2011)  Pharmacologic Substance
2010s  20         230      12.6%      nintedanib                                          2012 (2010)  Pharmacologic Substance
2000s  1          6248     2.61%      bevacizumab                                         2001 (1992)  Pharmacologic Substance
2000s  2          3130     3.93%      sorafenib                                           2004 (2004)  Pharmacologic Substance
2000s  3          3016     5.19%      imatinib                                            2001 (2001)  Pharmacologic Substance
2000s  4          2694     6.32%      bortezomib                                          2002 (2002)  Pharmacologic Substance
2000s  5          2646     7.43%      everolimus                                          2000 (1997)  Pharmacologic Substance
2000s  6          2501     8.48%      sunitinib                                           2005 (2005)  Pharmacologic Substance
2000s  7          2377     9.47%      erlotinib                                           2002 (2002)  Pharmacologic Substance
2000s  8          2290     10.4%      adalimumab                                          2002 (2002)  Pharmacologic Substance
2000s  9          1993     11.2%      cetuximab                                           2000 (1984)  Pharmacologic Substance
2000s  10         1932     12.0%      CXCL10                                              2001 (1974)  Pharmacologic Substance
2000s  11         1844     12.8%      rivaroxaban                                         2006 (2005)  Pharmacologic Substance
2000s  12         1801     13.6%      ranibizumab                                         2003 (2003)  Pharmacologic Substance
2000s  13         1788     14.3%      lenalidomide                                        2004 (2001)  Pharmacologic Substance
2000s  14         1771     15.1%      zoledronic acid                                     2000 (2000)  Clinical Drug
2000s  15         1527     15.7%      rosuvastatin                                        2001 (2001)  Pharmacologic Substance
2000s  16         1471     16.3%      gefitinib                                           2002 (2002)  Pharmacologic Substance
2000s  17         1469     16.9%      SP600125                                            2001 (2001)  Pharmacologic Substance
2000s  18         1454     17.5%      tigecycline                                         2002 (1999)  Organic Chemical
2000s  19         1371     18.1%      zoledronic acid                                     2000 (2000)  Pharmacologic Substance
2000s  20         1200     18.6%      denosumab                                           2005 (2005)  Pharmacologic Substance
1990s  1          16209    3.94%      IL10                                                1990 (1990)  Pharmacologic Substance
1990s  2          12716    7.03%      antiapoptotic                                       1992 (1992)  Chemical Viewed Functionally
1990s  3          11306    9.78%      carbon nanotubes                                    1992 (1969)  Chemical Viewed Structurally
1990s  4          7256     11.5%      rituximab                                           1997 (1987)  Pharmacologic Substance
1990s  5          6735     13.1%      paclitaxel                                          1993 (1993)  Pharmacologic Substance
1990s  6          3940     14.1%      IL13                                                1993 (1992)  Pharmacologic Substance
1990s  7          3747     15.0%      clopidogrel                                         1991 (1991)  Pharmacologic Substance
1990s  8          3408     15.8%      gemcitabine                                         1990 (1985)  Pharmacologic Substance
1990s  9          3402     16.7%      docetaxel                                           1993 (1993)  Pharmacologic Substance
1990s  10         2994     17.4%      trastuzumab                                         1998 (1990)  Pharmacologic Substance
1990s  11         2937     18.1%      carbon nanotube                                     1992 (1969)  Chemical Viewed Structurally
1990s  12         2738     18.8%      sirolimus                                           1994 (1975)  Organic Chemical
1990s  13         2699     19.4%      infliximab                                          1998 (1958)  Pharmacologic Substance
1990s  14         2687     20.1%      biodiesel                                           1994 (1994)  Organic Chemical
1990s  15         2651     20.7%      tacrolimus                                          1992 (1991)  Pharmacologic Substance
1990s  16         2296     21.3%      atorvastatin                                        1994 (1994)  Pharmacologic Substance
1990s  17         2210     21.8%      linezolid                                           1997 (1997)  Pharmacologic Substance
1990s  18         2138     22.3%      dendrimers                                          1990 (1980)  Biomedical or Dental Material
1990s  19         2104     22.9%      endocannabinoid                                     1997 (1991)  Biologically Active Substance
1990s  20         1940     23.3%      LY294002                                            1994 (1994)  Pharmacologic Substance
1980s  1          14480    2.61%      IL6                                                 1987 (1982)  Pharmacologic Substance
1980s  2          13347    5.02%      VEGF                                                1987 (1952)  Pharmacologic Substance
1980s  3          9907     6.81%      signaling molecule                                  1982 (1982)  Biologically Active Substance
1980s  4          8898     8.42%      interleukin6                                        1987 (1982)  Pharmacologic Substance
1980s  5          6787     9.64%      HER2                                                1987 (1987)  Pharmacologic Substance
1980s  6          6216     10.7%      statins                                             1983 (1949)  Pharmacologic Substance
1980s  7          6056     11.8%      IL8                                                 1989 (1969)  Pharmacologic Substance
1980s  8          5397     12.8%      3UTR                                                1984 (1984)  Biologically Active Substance
1980s  9          4941     13.7%      oxaliplatin                                         1989 (1989)  Clinical Drug
1980s  10         4814     14.5%      brainderived neurotrophic factor                    1985 (1985)  Pharmacologic Substance
1980s  11         4691     15.4%      ciprofloxacin                                       1983 (1983)  Pharmacologic Substance
1980s  12         4630     16.2%      ciprofloxacin                                       1983 (1983)  Organic Chemical
1980s  13         4199     17.0%      IGF1                                                1980 (1974)  Pharmacologic Substance
1980s  14         3791     17.7%      propofol                                            1984 (1980)  Pharmacologic Substance
1980s  15         3571     18.3%      vascular endothelial growth factor                  1982 (1952)  Pharmacologic Substance
1980s  16         3538     19.0%      interleukin                                         1980 (1980)  Pharmacologic Substance
1980s  17         3535     19.6%      protein kinase C                                    1981 (1981)  Pharmacologic Substance
1980s  18         3490     20.2%      interleukin1                                        1980 (1970)  Pharmacologic Substance
1980s  19         3433     20.8%      fluconazole                                         1985 (1985)  Clinical Drug
1980s  20         3298     21.4%      temozolomide                                        1988 (1988)  Clinical Drug
1970s  1          13252    2.36%      monoclonal antibodies                               1971 (1971)  Clinical Drug
1970s  2          10750    4.28%      doxorubicin                                         1972 (1949)  Organic Chemical
1970s  3          8736     5.84%      logran                                              1973 (1973)  Pharmacologic Substance
1970s  4          8044     7.27%      intron                                              1978 (1978)  Pharmacologic Substance
1970s  5          7741     8.65%      monoclonal antibodies                               1971 (1971)  Pharmacologic Substance
1970s  6          7047     9.91%      cisplatin                                           1971 (1970)  Pharmacologic Substance
1970s  7          6346     11.0%      immunomodulator                                     1976 (1949)  Pharmacologic Substance
1970s  8          5985     12.1%      peroxisome proliferator                             1975 (1975)  Hazardous or Poisonous Substance
1970s  9          5841     13.1%      tumor necrosis factor                               1975 (1975)  Pharmacologic Substance
1970s  10         5465     14.1%      rapamycin                                           1975 (1975)  Organic Chemical
1970s  11         4992     15.0%      25hydroxyvitamin D                                  1973 (1973)  Vitamin
1970s  12         4797     15.8%      pristine                                            1974 (1974)  Hazardous or Poisonous Substance
1970s  13         4339     16.6%      IL1                                                 1976 (1970)  Pharmacologic Substance
1970s  14         4319     17.4%      pristine                                            1974 (1974)  Organic Chemical
1970s  15         4179     18.1%      25hydroxyvitamin D                                  1973 (1968)  Pharmacologic Substance
1970s  16         4053     18.8%      antimicrobial peptide                               1979 (1979)  Pharmacologic Substance
1970s  17         3232     19.4%      resveratrol                                         1978 (1978)  Pharmacologic Substance
1970s  18         3122     20.0%      LDL cholesterol                                     1972 (1955)  Biologically Active Substance
1970s  19         2682     20.5%      angiogenic factor                                   1973 (1972)  Biologically Active Substance
1970s  20         2639     20.9%      tumor markers                                       1973 (1973)  Biologically Active Substance
1960s  1          52920    7.17%      ligands                                             1960 (1949)  Chemical
1960s  2          15286    9.24%      superoxide dismutase                                1969 (1969)  Organic Chemical
1960s  3          13413    11.0%      COPD                                                1967 (1967)  Pharmacologic Substance
1960s  4          10744    12.5%      superoxide dismutase                                1969 (1949)  Pharmacologic Substance
1960s  5          9858     13.8%      molecular target                                    1969 (1969)  Chemical Viewed Functionally
1960s  6          9517     15.1%      xenografts                                          1962 (1949)  Biomedical or Dental Material
1960s  7          9335     16.4%      xenograft                                           1962 (1949)  Biomedical or Dental Material
1960s  8          9068     17.6%      opioids                                             1968 (1968)  Biologically Active Substance
1960s  9          8209     18.7%      allograft                                           1963 (1949)  Biomedical or Dental Material
1960s  10         7872     19.8%      biomaterials                                        1967 (1967)  Biomedical or Dental Material
1960s  11         6333     20.6%      bioi                                                1960 (1960)  Inorganic Chemical
1960s  12         5967     21.4%      dopaminergic                                        1964 (1964)  Pharmacologic Substance
1960s  13         5773     22.2%      hotspot                                             1961 (1961)  Pharmacologic Substance
1960s  14         5431     22.9%      CI 4                                                1960 (1960)  Pharmacologic Substance
1960s  15         5414     23.7%      hydrogels                                           1964 (1964)  Biomedical or Dental Material
1960s  16         5038     24.4%      pahs                                                1965 (1949)  Organic Chemical
1960s  17         4882     25.0%      immunosuppressive                                   1963 (1963)  Pharmacologic Substance
1960s  18         4712     25.7%      neurotransmitters                                   1962 (1955)  Biologically Active Substance
1960s  19         4677     26.3%      opioids                                             1968 (1949)  Pharmacologic Substance
1960s  20         3803     26.8%      allografts                                          1963 (1949)  Biomedical or Dental Material
1950s  1          17863    2.36%      remodelin                                           1950 (1950)  Pharmacologic Substance
1950s  2          17123    4.63%      oncogen                                             1950 (1949)  Hazardous or Poisonous Substance
1950s  3          15506    6.68%      lipopolysaccharide                                  1950 (1950)  Organic Chemical
1950s  4          13158    8.42%      malondialdehyde                                     1951 (1951)  Biologically Active Substance
1950s  5          11963    10.0%      mimics                                              1950 (1949)  Hazardous or Poisonous Substance
1950s  6          11734    11.5%      surfactant                                          1951 (1951)  Biologically Active Substance
1950s  7          11396    13.0%      arabidopsis thaliana                                1955 (1955)  Organic Chemical
1950s  8          10802    14.5%      surfactant                                          1951 (1949)  Biomedical or Dental Material
1950s  9          8975     15.6%      surfactant                                          1951 (1951)  Chemical Viewed Functionally
1950s  10         8534     16.8%      pollutants                                          1950 (1950)  Hazardous or Poisonous Substance
1950s  11         7060     17.7%      predef                                              1950 (1950)  Pharmacologic Substance
1950s  12         7048     18.6%      streptozotocin                                      1959 (1959)  Organic Chemical
1950s  13         6844     19.5%      hydrogel                                            1955 (1955)  Pharmacologic Substance
1950s  14         6840     20.4%      cortisol                                            1954 (1949)  Pharmacologic Substance
1950s  15         6690     21.3%      interferon                                          1957 (1957)  Pharmacologic Substance
1950s  16         6588     22.2%      virulence factors                                   1952 (1949)  Hazardous or Poisonous Substance
1950s  17         6406     23.1%      dopamine                                            1952 (1949)  Pharmacologic Substance
1950s  18         6239     23.9%      neurotransmitter                                    1955 (1955)  Biologically Active Substance
1950s  19         5924     24.7%      surfactants                                         1951 (1951)  Chemical Viewed Functionally
1950s  20         5866     25.4%      agonist                                             1952 (1952)  Pharmacologic Substance
BASIC SCIENCE AND RESEARCH TOOLS (3rd of 4 idea category groups)
2010s  1          663      .666%      mechanistic target of rapamycin                     2010 (1971)  Amino Acid, Peptide, or Protein
2010s  2          658      1.32%      mechanistic target of rapamycin                     2010 (1976)  Gene or Genome
2010s  3          648      1.97%      middle east respiratory syndrome coronavirus        2013 (1999)  Virus
2010s  4          403      2.38%      transcription activatorlike effector nucleases      2011 (2010)  Amino Acid, Peptide, or Protein
2010s  5          323      2.70%      AMPK1                                               2010 (1985)  Gene or Genome
2010s  6          304      3.01%      H7N9 virus                                          2013 (2013)  Virus
2010s  7          301      3.31%      C9ORF72                                             2011 (2011)  Gene or Genome
2010s  8          295      3.61%      schmallenberg virus                                 2012 (2012)  Virus
2010s  9          276      3.88%      talens                                              2010 (2010)  Amino Acid, Peptide, or Protein
2010s  10         256      4.14%      interleukin28b                                      2010 (2003)  Amino Acid, Peptide, or Protein
2010s  11         246      4.39%      crisprcas systems                                   2011 (2006)  Molecular Function
2010s  12         219      4.61%      mechanistic target of rapamycin complex 1           2010 (2002)  Amino Acid, Peptide, or Protein
2010s  13         214      4.82%      telocytes                                           2010 (2005)  Cell
2010s  14         191      5.02%      SRSF2                                               2011 (1991)  Amino Acid, Peptide, or Protein
2010s  15         182      5.20%      chromothripsis                                      2011 (1954)  Cell or Molecular Dysfunction
2010s  16         179      5.38%      CALR mutation                                       2013 (2013)  Cell or Molecular Dysfunction
2010s  17         164      5.54%      fukushima nuclear accident                          2011 (2011)  Human-caused Phenomenon or Process
2010s  18         162      5.71%      beige adipocytes                                    2012 (2010)  Cell
2010s  19         151      5.86%      SRSF2                                               2011 (1991)  Gene or Genome
2010s  20         150      6.01%      ocriplasmin                                         2010 (1987)  Amino Acid, Peptide, or Protein
2000s  1          21210    3.08%      micrornas                                           2001 (1971)  Nucleic Acid, Nucleoside, or Nucleotide
2000s  2          12390    4.88%      microrna                                            2000 (1971)  Nucleic Acid, Nucleoside, or Nucleotide
2000s  3          9139     6.21%      nextgeneration sequencing                           2007 (2005)  Molecular Biology Research Technique
2000s  4          8606     7.46%      small interfering RNA                               2001 (1949)  Nucleic Acid, Nucleoside, or Nucleotide
2000s  5          6569     8.42%      GWAS                                                2007 (1982)  Molecular Biology Research Technique
2000s  6          4290     9.04%      induced pluripotent stem cells                      2006 (1966)  Cell
2000s  7          3885     9.61%      th17 cells                                          2006 (1980)  Cell
2000s  8          3405     10.1%      deep sequencing                                     2000 (2000)  Molecular Biology Research Technique
2000s  9          3055     10.5%      mtorc1                                              2004 (2002)  Cell Component
2000s  10         2976     10.9%      IL17A                                               2003 (1988)  Amino Acid, Peptide, or Protein
2000s  11         2746     11.3%      IL17A                                               2003 (1988)  Gene or Genome
2000s  12         2667     11.7%      CD133                                               2000 (2000)  Amino Acid, Peptide, or Protein
2000s  13         2651     12.1%      inflammasome                                        2002 (2002)  Amino Acid, Peptide, or Protein
2000s  14         2532     12.5%      short hairpin RNA                                   2002 (1982)  Nucleic Acid, Nucleoside, or Nucleotide
2000s  15         2520     12.8%      exome sequencing                                    2009 (2009)  Molecular Biology Research Technique
2000s  16         2513     13.2%      CD133                                               2000 (1978)  Gene or Genome
2000s  17         2466     13.6%      norovirus                                           2002 (2002)  Amino Acid, Peptide, or Protein
2000s  18         2411     13.9%      small interfering rna                               2001 (1949)  Nucleic Acid, Nucleoside, or Nucleotide
2000s  19         2318     14.3%      IL23                                                2000 (2000)  Molecular Function
2000s  20         2265     14.6%      long noncoding RNA                                  2007 (2003)  Nucleic Acid, Nucleoside, or Nucleotide
1990s  1          20439    1.19%      graphene                                            1992 (1992)  Element, Ion, or Isotope
1990s  2          20423    2.39%      realtime PCR                                        1996 (1989)  Molecular Biology Research Technique
1990s  3          18527    3.47%      single nucleotide polymorphisms                     1994 (1966)  Nucleotide Sequence
1990s  4          17023    4.46%      IL10                                                1990 (1990)  Molecular Function
1990s  5          14482    5.31%      transcriptome                                       1997 (1997)  Nucleotide Sequence
1990s  6          14459    6.16%      caspase3                                            1997 (1949)  Gene or Genome
1990s  7          13862    6.97%      caspase3                                            1997 (1949)  Amino Acid, Peptide, or Protein
1990s  8          11694    7.65%      PI3K                                                1990 (1989)  Molecular Function
1990s  9          10248    8.25%      nanomaterials                                       1994 (1994)  Research Activity
1990s  10         9951     8.83%      qrtpcr                                              1997 (1992)  Molecular Biology Research Technique
1990s  11         9237     9.37%      IL10                                                1990 (1975)  Gene or Genome
1990s  12         8821     9.89%      MAPK                                                1990 (1959)  Molecular Function
1990s  13         8771     10.4%      quantitative realtime PCR                           1999 (1989)  Molecular Biology Research Technique
1990s  14         8459     10.9%      MMP9                                                1991 (1991)  Molecular Function
1990s  15         8432     11.3%      IL10                                                1990 (1975)  Amino Acid, Peptide, or Protein
1990s  16         8158     11.8%      adiponectin                                         1999 (1966)  Gene or Genome
1990s  17         7965     12.3%      realtime polymerase chain reaction                  1997 (1989)  Molecular Biology Research Technique
1990s  18         7533     12.7%      adiponectin                                         1999 (1982)  Amino Acid, Peptide, or Protein
1990s  19         7429     13.2%      single nucleotide polymorphism                      1991 (1966)  Nucleotide Sequence
1990s  20         6443     13.5%      PI3K                                                1990 (1975)  Gene or Genome
1980s  1          52779    2.85%      signaling pathway                                   1984 (1949)  Cell Function
1980s  2          41362    5.10%      signaling pathway                                   1984 (1984)  Molecular Function
1980s  3          31713    6.81%      polymerase chain reaction                           1986 (1986)  Molecular Biology Research Technique
1980s  4          29573    8.42%      RTPCR                                               1989 (1989)  Molecular Biology Research Technique
1980s  5          22089    9.61%      IL6                                                 1987 (1987)  Molecular Function
1980s  6          17648    10.5%      western blotting                                    1981 (1980)  Molecular Biology Research Technique
1980s  7          16542    11.4%      western blot                                        1981 (1980)  Molecular Biology Research Technique
1980s  8          14755    12.2%      metaanalyses                                        1982 (1975)  Research Activity
1980s  9          13893    13.0%      MTT assay                                           1985 (1985)  Research Activity
1980s  10         13784    13.7%      HIV1                                                1986 (1984)  Virus
1980s  11         13393    14.4%      vascular endothelial growth factor                  1982 (1982)  Molecular Function
1980s  12         12584    15.1%      bcl2                                                1984 (1984)  Molecular Function
1980s  13         12158    15.8%      tandem mass spectrometry                            1981 (1952)  Molecular Biology Research Technique
1980s  14         11356    16.4%      RNA interference                                    1987 (1959)  Genetic Function
1980s  15         10633    17.0%      EGFR                                                1980 (1979)  Molecular Function
1980s  16         10614    17.6%      quantitative PCR                                    1989 (1989)  Molecular Biology Research Technique
1980s  17         10205    18.1%      human immunodeficiency virus                        1986 (1983)  Virus
1980s  18         9966     18.6%      hepatitis C virus HCV                               1989 (1961)  Virus
1980s  19         8766     19.1%      mscs                                                1980 (1980)  Molecular Function
1980s  20         8766     19.6%      VEGF                                                1987 (1987)  Gene or Genome
1970s  1          88250    3.17%      targeting                                           1971 (1969)  Cell Function
1970s  2          71032    5.73%      apoptosis                                           1972 (1965)  Cell Function
1970s  3          69386    8.23%      oxidative stress                                    1970 (1970)  Cell or Molecular Dysfunction
1970s  4          64508    10.5%      logistic regression                                 1974 (1974)  Research Activity
1970s  5          60211    12.7%      overexpression                                      1977 (1977)  Genetic Function
1970s  6          54912    14.7%      upregulation                                        1979 (1972)  Genetic Function
1970s  7          52661    16.6%      metaanalysis                                        1977 (1975)  Research Activity
1970s  8          45151    18.2%      reactive oxygen species                             1977 (1949)  Element, Ion, or Isotope
1970s  9          37086    19.5%      upregulation                                        1979 (1979)  Molecular Function
1970s  10         36853    20.8%      mrna expression                                     1979 (1949)  Genetic Function
1970s  11         35969    22.1%      protein expression                                  1976 (1949)  Genetic Function
1970s  12         28786    23.2%      logistic regression analysis                        1974 (1974)  Research Activity
1970s  13         23896    24.0%      overexpress                                         1977 (1977)  Genetic Function
1970s  14         23598    24.9%      randomized controlled trial                         1970 (1970)  Research Activity
1970s  15         22945    25.7%      downregulation                                      1977 (1977)  Molecular Function
1970s  16         20421    26.5%      CD8                                                 1979 (1976)  Immunologic Factor
1970s  17         19721    27.2%      T cells                                             1970 (1967)  Cell
1970s  18         17182    27.8%      FTIR                                                1975 (1972)  Research Activity
1970s  19         16625    28.4%      ANOVA                                               1971 (1971)  Gene or Genome
1970s  20         16541    29.0%      ANOVA                                               1971 (1971)  Amino Acid, Peptide, or Protein
1960s  1          86187    3.94%      mrna                                                1964 (1961)  Nucleic Acid, Nucleoside, or Nucleotide
1960s  2          83131    7.75%      targeted                                            1969 (1969)  Cell Function
1960s  3          60306    10.5%      gene expression                                     1961 (1949)  Genetic Function
1960s  4          45781    12.6%      crosssectional study                                1961 (1954)  Research Activity
1960s  5          32420    14.0%      genomic                                             1961 (1949)  Gene or Genome
1960s  6          31775    15.5%      transcriptional                                     1966 (1949)  Genetic Function
1960s  7          24042    16.6%      extracellular matrix                                1962 (1952)  Tissue
1960s  8          18772    17.5%      transcripts                                         1962 (1949)  Nucleic Acid, Nucleoside, or Nucleotide
1960s  9          18060    18.3%      casecontrol study                                   1967 (1967)  Research Activity
1960s  10         18018    19.1%      phylogenetic analysis                               1964 (1949)  Research Activity
1960s  11         16077    19.9%      16S rrna                                            1968 (1966)  Nucleic Acid, Nucleoside, or Nucleotide
1960s  12         15664    20.6%      retrospective cohort study                          1966 (1966)  Research Activity
1960s  13         15057    21.3%      translational                                       1963 (1949)  Genetic Function
1960s  14         14371    21.9%      chiral                                              1968 (1949)  Phenomenon or Process
1960s  15         14303    22.6%      COPD                                                1967 (1967)  Gene or Genome
1960s  16         14096    23.2%      DNA damage                                          1965 (1965)  Cell or Molecular Dysfunction
1960s  17         13568    23.8%      immunosuppression                                   1964 (1964)  Organism Function
1960s  18         13020    24.4%      transfection                                        1966 (1966)  Molecular Biology Research Technique
1960s  19         11614    25.0%      drug discovery                                      1964 (1964)  Research Activity
1960s  20         10962    25.5%      eukaryotes                                          1968 (1956)  Eukaryote
1950s  1          64715    3.69%      randomized                                          1953 (1949)  Research Activity
1950s  2          59508    7.09%      recombinant                                         1951 (1951)  Organism
1950s  3          56353    10.3%      simulations                                         1954 (1949)  Research Activity
1950s  4          33856    12.2%      selfreport                                          1953 (1953)  Research Activity
1950s  5          33379    14.1%      prospective study                                   1954 (1954)  Research Activity
1950s  6          25870    15.6%      polymorphisms                                       1952 (1949)  Genetic Function
1950s  7          17037    16.5%      cterminal                                           1952 (1952)  Amino Acid Sequence
1950s  8          16458    17.5%      oligomer                                            1958 (1958)  Amino Acid Sequence
1950s  9          16243    18.4%      reperfusion                                         1952 (1952)  Biologic Function
1950s  10         14279    19.2%      cloned                                              1958 (1949)  Cell
1950s  11         14238    20.0%      binding sites                                       1952 (1949)  Receptor
1950s  12         13733    20.8%      ecosystems                                          1959 (1956)  Natural Phenomenon or Process
1950s  13         13641    21.6%      genetic diversity                                   1959 (1949)  Natural Phenomenon or Process
1950s  14         11997    22.3%      binding site                                        1952 (1952)  Amino Acid Sequence
1950s  15         11940    23.0%      genomes                                             1957 (1949)  Gene or Genome
1950s  16         11873    23.7%      data collection                                     1952 (1952)  Research Activity
1950s  17         11186    24.3%      hepatocytes                                         1956 (1949)  Cell
1950s  18         11107    24.9%      binding site                                        1952 (1949)  Receptor
1950s  19         10352    25.5%      placebocontrolled                                   1954 (1953)  Research Activity
1950s  20         10160    26.1%      exon                                                1950 (1950)  Nucleic Acid, Nucleoside, or Nucleotide
MISCELLANEOUS (4th of 4 idea category groups)
2010s  1          1105     3.28%      patient protection and affordable care act          2010 (1981)  Regulation or Law
2010s  2          569      4.98%      cha2ds2vasc score                                   2010 (2010)  Intellectual Product
2010s  3          262      5.76%      HASBLED score                                       2011 (2011)  Intellectual Product
2010s  4          173      6.27%      PAM50                                               2010 (2010)  Functional Concept
2010s  5          161      6.75%      vaping                                              2011 (1970)  Individual Behavior
2010s  6          155      7.21%      affordable care acts                                2010 (1981)  Regulation or Law
2010s  7          148      7.65%      human connectome project                            2011 (2011)  Biomedical Occupation or Discipline
2010s  8          100      7.95%      prostate imaging reporting and data system          2013 (2012)  Classification
2010s  9          100      8.25%      prostate imaging reporting and data system          2013 (2013)  Intellectual Product
2010s  10         79       8.48%      PIRADS                                              2012 (2012)  Classification
2010s  11         76       8.71%      level of evidence II                                2010 (2010)  Conceptual Entity
2010s  12         74       8.93%      soft robotics                                       2011 (2001)  Occupation or Discipline
2010s  13         73       9.15%      3D printed model                                    2013 (2013)  Manufactured Object
2010s  14         69       9.35%      operation new dawn                                  2011 (2011)  Idea or Concept
2010s  15         58       9.53%      activity trackers                                   2012 (2012)  Manufactured Object
2010s  16         56       9.69%      standard uptake value ratio                         2010 (1991)  Quantitative Concept
2010s  17         51       9.84%      national center for advancing translational sciences  2011 (1990)  Health Care Related Organization
2010s  18         51       10.0%      groningen frailty indicator                         2010 (2010)  Intellectual Product
2010s  19         49       10.1%      grch37                                              2010 (2010)  Intellectual Product
2010s  20         48       10.2%      nannochloropsis oceanica                            2011 (2011)  Plant
2000s  1          8547     5.76%      regenerative medicine                               2000 (2000)  Biomedical Occupation or Discipline
2000s  2          7193     10.6%      metabolomics                                        2000 (1951)  Biomedical Occupation or Discipline
2000s  3          6827     15.2%      gene ontology                                       2000 (2000)  Intellectual Product
2000s  4          3136     17.3%      metagenomic                                         2000 (1987)  Occupation or Discipline
2000s  5          2883     19.2%      metabolomic                                         2000 (1951)  Biomedical Occupation or Discipline
2000s  6          2686     21.1%      DSM5                                                2000 (2000)  Intellectual Product
2000s  7          2172     22.5%      smartphone                                          2004 (2004)  Manufactured Object
2000s  8          1791     23.7%      metagenomics                                        2003 (1987)  Occupation or Discipline
2000s  9          1525     24.8%      theranostic                                         2000 (2000)  Biomedical Occupation or Discipline
2000s  10         1503     25.8%      smartphones                                         2004 (2004)  Manufactured Object
2000s  11         1438     26.7%      MELD score                                          2001 (2001)  Intellectual Product
2000s  12         1401     27.7%      RECIST                                              2000 (2000)  Intellectual Product
2000s  13         1287     28.6%      nanoribbons                                         2000 (2000)  Manufactured Object
2000s  14         1283     29.4%      model for endstage liver disease                    2001 (1988)  Classification
2000s  15         1200     30.2%      response evaluation criteria in solid tumors        2000 (2000)  Intellectual Product
2000s  16         1171     31.0%      hapmap                                              2002 (2002)  Organism Attribute
2000s  17         1100     31.8%      common terminology criteria for adverse events      2003 (1991)  Intellectual Product
2000s  18         1042     32.5%      centers for medicare and medicaid services          2001 (1977)  Health Care Related Organization
2000s  19         1032     33.2%      montreal cognitive assessment                       2005 (1960)  Intellectual Product
2000s  20         939      33.8%      agency for healthcare research and quality          2000 (1990)  Health Care Related Organization
1990s  1          27976    6.07%      microarray                                          1992 (1992)  Manufactured Object
1990s  2          16380    9.63%      proteomics                                          1997 (1997)  Biomedical Occupation or Discipline
1990s  3          15358    12.9%      proteomic                                           1997 (1997)  Biomedical Occupation or Discipline
1990s  4          11317    15.4%      knockout mice                                       1992 (1978)  Mammal
1990s  5          9075     17.4%      nanomaterials                                       1994 (1986)  Manufactured Object
1990s  6          6885     18.9%      nanowires                                           1993 (1993)  Manufactured Object
1990s  7          6540     20.3%      SF36                                                1991 (1991)  Intellectual Product
1990s  8          5950     21.6%      nanotechnology                                      1991 (1991)  Occupation or Discipline
1990s  9          5366     22.7%      innate immune response                              1993 (1949)  Organism Attribute
1990s  10         5090     23.8%      nanorods                                            1999 (1999)  Manufactured Object
1990s  11         4868     24.9%      men who have sex with men                           1991 (1991)  Population Group
1990s  12         4702     25.9%      systems biology                                     1993 (1993)  Biomedical Occupation or Discipline
1990s  13         4546     26.9%      evidencebased practice                              1993 (1993)  Functional Concept
1990s  14         4522     27.9%      support vector machine                              1998 (1998)  Quantitative Concept
1990s  15         4458     28.9%      centers for disease control and prevention          1991 (1971)  Health Care Related Organization
1990s  16         4438     29.8%      nanofibers                                          1994 (1994)  Manufactured Object
1990s  17         4331     30.8%      clinical practice guidelines                        1990 (1990)  Intellectual Product
1990s  18         4168     31.7%      evidencebased medicine                              1992 (1992)  Biomedical Occupation or Discipline
1990s  19         3897     32.5%      affymetrix                                          1995 (1995)  Health Care Related Organization
1990s  20         3826     33.3%      innate immune responses                             1995 (1949)  Organism Attribute
1980s  1          39848    4.54%      hazard ratio                                        1980 (1980)  Quantitative Concept
1980s  2          39599    9.06%      comorbidities                                       1986 (1970)  Idea or Concept
1980s  3          17746    11.0%      progressionfree survival                            1983 (1983)  Quantitative Concept
1980s  4          15786    12.8%      stakeholder                                         1981 (1981)  Conceptual Entity
1980s  5          15321    14.6%      bioinformatics                                      1989 (1988)  Biomedical Occupation or Discipline
1980s  6          15038    16.3%      healthrelated quality of life                       1982 (1982)  Idea or Concept
1980s  7          13421    17.8%      molecular dynamics simulations                      1981 (1973)  Machine Activity
1980s  8          11555    19.2%      focus groups                                        1980 (1977)  Group
1980s  9          10754    20.4%      biodiversity                                        1988 (1968)  Qualitative Concept
1980s  10         10658    21.6%      transgenic mice                                     1982 (1982)  Mammal
1980s  11         10558    22.8%      electronic database                                 1980 (1980)  Intellectual Product
1980s  12         8609     23.8%      microfluidic                                        1988 (1988)  Occupation or Discipline
1980s  13         8220     24.7%      nanostructures                                      1986 (1986)  Manufactured Object
1980s  14         6864     25.5%      bioinformatic                                       1988 (1988)  Biomedical Occupation or Discipline
1980s  15         6864     26.3%      primary outcome measure                             1981 (1981)  Qualitative Concept
1980s  16         6852     27.1%      propensity score                                    1987 (1987)  Quantitative Concept
1980s  17         6804     27.8%      gene expression profiles                            1989 (1989)  Quantitative Concept
1980s  18         6312     28.6%      nanostructure                                       1986 (1986)  Manufactured Object
1980s  19         6123     29.3%      quantum dots                                        1987 (1987)  Manufactured Object
1980s  20         6114     30.0%      african americans                                   1980 (1949)  Population Group
1970s  1          109968   4.43%      targeting                                           1971 (1949)  Functional Concept
1970s  2          71641    7.32%      odds ratio                                          1970 (1970)  Quantitative Concept
1970s  3          62961    9.86%      magnetic resonance imaging                          1978 (1978)  Professional or Occupational Group
1970s  4          58091    12.2%      expression level                                    1979 (1979)  Quantitative Concept
1970s  5          54297    14.4%      metaanalysis                                        1977 (1977)  Intellectual Product
1970s  6          52768    16.5%      nanoparticles                                       1978 (1978)  Manufactured Object
1970s  7          34573    17.9%      inclusion criteria                                  1976 (1949)  Qualitative Concept
1970s  8          33562    19.2%      dataset                                             1970 (1949)  Intellectual Product
1970s  9          32970    20.6%      apoptotic                                           1972 (1972)  Qualitative Concept
1970s  10         26379    21.6%      scenarios                                           1974 (1949)  Functional Concept
1970s  11         25440    22.7%      IC50                                                1970 (1965)  Quantitative Concept
1970s  12         24189    23.6%      gold standard                                       1979 (1979)  Qualitative Concept
1970s  13         23802    24.6%      databases                                           1971 (1949)  Intellectual Product
1970s  14         22336    25.5%      transgenic                                          1972 (1972)  Animal
1970s  15         22291    26.4%      odds ratios                                         1978 (1970)  Quantitative Concept
1970s  16         18359    27.1%      comorbidity                                         1970 (1970)  Idea or Concept
1970s  17         18025    27.9%      patient outcome                                     1970 (1970)  Idea or Concept
1970s  18         17325    28.6%      risk assessment                                     1973 (1973)  Intellectual Product
1970s  19         17232    29.3%      scaffolds                                           1975 (1949)  Manufactured Object
1970s  20         16241    29.9%      nonsmall cell lung cancer                           1976 (1976)  Conceptual Entity
1960s  1          89643    3.02%      targeted                                            1969 (1949)  Functional Concept
1960s  2          56711    4.93%      software                                            1965 (1960)  Manufactured Object
1960s  3          54652    6.77%      ongoing                                             1960 (1949)  Idea or Concept
1960s  4          53347    8.57%      genomic                                             1961 (1961)  Biomedical Occupation or Discipline
1960s  5          51686    10.3%      optimization                                        1960 (1960)  Activity
1960s  6          51434    12.0%      sequencing                                          1962 (1962)  Functional Concept
1960s  7          44072    13.5%      sequencing                                          1962 (1962)  Intellectual Product
1960s  8          38380    14.8%      time point                                          1960 (1955)  Temporal Concept
1960s  9          36566    16.0%      dosedependent                                       1960 (1960)  Quantitative Concept
1960s  10         35745    17.2%      animal models                                       1962 (1954)  Animal
1960s  11         32058    18.3%      colorectal cancer                                   1962 (1962)  Conceptual Entity
1960s  12         30573    19.3%      automated                                           1960 (1949)  Functional Concept
1960s  13         28157    20.3%      transcripts                                         1962 (1962)  Intellectual Product
1960s  14         27647    21.2%      providers                                           1960 (1949)  Functional Concept
1960s  15         26162    22.1%      colorectal cancer                                   1962 (1962)  Intellectual Product
1960s  16         24749    22.9%      overall survival                                    1963 (1963)  Quantitative Concept
1960s  17         23419    23.7%      ethnicity                                           1966 (1966)  Qualitative Concept
1960s  18         22479    24.5%      algorithms                                          1963 (1949)  Intellectual Product
1960s  19         21854    25.2%      ex vivo                                             1964 (1964)  Functional Concept
1960s  20         19862    25.9%      ethnicity                                           1966 (1949)  Population Group
1950s  1          101395   2.49%      risk factors                                        1959 (1959)  Intellectual Product
1950s  2          67299    4.15%      quality of life                                     1959 (1959)  Idea or Concept
1950s  3          62097    5.68%      encoding                                            1956 (1953)  Activity
1950s  4          62041    7.21%      encoding                                            1956 (1956)  Idea or Concept
1950s  5          52107    8.50%      downstream                                          1950 (1950)  Spatial Concept
1950s  6          50147    9.73%      researchers                                         1954 (1949)  Professional or Occupational Group
1950s  7          46112    10.8%      documented                                          1950 (1950)  Intellectual Product
1950s  8          41331    11.8%      technologies                                        1956 (1949)  Occupation or Discipline
1950s  9          38756    12.8%      options                                             1950 (1949)  Functional Concept
1950s  10         33842    13.6%      modulating                                          1955 (1949)  Spatial Concept
1950s  11         31872    14.4%      intraoperative                                      1950 (1950)  Temporal Concept
1950s  12         30024    15.2%      categorized                                         1957 (1952)  Activity
1950s  13         29996    15.9%      encode                                              1953 (1953)  Activity
1950s  14         29951    16.6%      older adult                                         1951 (1951)  Age Group
1950s  15         28595    17.3%      lifestyle                                           1959 (1956)  Social Behavior
1950s  16         28278    18.0%      perioperative                                       1957 (1957)  Temporal Concept
1950s  17         26289    18.7%      older adult                                         1951 (1949)  Population Group
1950s  18         25647    19.3%      emergency department                                1957 (1957)  Health Care Related Organization
1950s  19         25130    19.9%      encoded                                             1953 (1953)  Activity
1950s  20         25019    20.6%      multidisciplinary                                   1952 (1949)  Occupational Activity
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Table S4. Bootstrapped Confidence Intervals and Robustness of Overall Frontier Positions of 
Nations to Alternative Specifications. 
 
(1a) (1b) (1c) (1d) (2) (3) (4) (5) (6) (7) (8) (9)
Location Number of 
Contributions
2010s;
same 
as 
column 
1c in 
Table 1
Bootstrapped 
95% 
Confidence 
Intervals
Set 
missing 
values 
equal 
to 0
Weight 
by 
number 
of own 
contri-
butions
Use UMLS 
synonym 
data to 
determine 
cohort of 
each term
Top 
20% 
novel 
status 
used
Top 
10% 
novel 
status 
used
Top  
1% 
novel 
status 
used
All 
papers 
(not just 
original 
res. 
papers)
No upper, 
lower 
limits on 
number 
of char-
acters
UNITED STATES 2853661 108 (106..109) 108 107 102 105 114 108 107 108
SOUTH KOREA 374227 107 (104..110) 105 107 108 108 99 107 108 106
SINGAPORE 52541 105 (100..111) 98 108 99 103 118 106 106 105
TAIWAN 177229 104 (101..107) 102 103 107 107 98 103 105 104
IRELAND 39495 103 (97..108) 95 100 98 98 109 101 102 100
BELGIUM 95644 102 (99..106) 99 102 99 100 104 104 101 101
ITALY 384029 102 (99..104) 101 103 100 102 100 102 103 102
CHINA 1734035 101 (99..103) 101 102 105 102 95 102 101 101
CANADA 375846 101 (99..104) 101 101 98 100 105 99 101 102
JAPAN 554589 100 (98..103) 99 103 100 100 100 100 101 100
UNITED KINGDOM 494917 100 (98..103) 100 100 97 98 105 100 100 100
NETHERLANDS 233631 100 (97..103) 99 100 99 99 100 100 100 100
GERMANY 539888 100 (98..102) 99 99 97 98 101 100 99 99
SWITZERLAND 123779 100 (96..103) 97 100 97 98 102 100 101 99
SAUDI ARABIA 34855 99 (94..106) 90 94 95 95 82 97 98 98
FINLAND 59534 99 (94..103) 94 98 100 98 96 98 99 98
NORWAY 63699 98 (93..103) 94 95 96 95 96 97 97 99
SOUTH AFRICA 43179 98 (92..104) 90 101 99 103 92 100 96 97
SPAIN 278504 98 (95..100) 97 97 98 98 92 99 97 97
CZECH REPUBLIC 44024 97 (92..102) 89 102 98 99 92 98 99 97
AUSTRALIA 320955 97 (95..99) 96 97 97 97 96 98 97 97
SWEDEN 138949 96 (92..99) 94 96 96 95 92 96 96 96
AUSTRIA 65039 96 (91..100) 91 97 96 97 99 96 96 96
DENMARK 105066 95 (92..99) 93 95 97 96 99 97 95 95
FRANCE 305065 95 (93..98) 94 96 95 96 98 98 95 96
POLAND 113074 93 (89..96) 90 93 94 93 90 90 93 93
THAILAND 40080 93 (87..98) 85 92 96 95 84 93 95 92
HUNGARY 28574 92 (86..99) 82 94 94 93 86 95 94 90
ISRAEL 76781 92 (88..96) 89 93 95 94 90 94 92 92
OTHER EUROPE 107712 90 (87..94) 88 90 92 90 88 90 92 90
NEW ZEALAND 38946 90 (84..96) 83 91 90 90 96 93 98 93
TURKEY 157825 90 (86..94) 87 91 95 94 84 90 90 89
RUSSIA 51759 89 (83..95) 79 89 87 86 90 86 90 89
CHILE 23794 89 (82..97) 78 88 95 92 71 96 87 89
GREECE 46646 89 (84..93) 83 92 98 93 81 92 90 90
MALAYSIA 37997 87 (82..93) 79 89 91 86 86 84 92 87
PORTUGAL 65523 86 (82..91) 82 86 91 89 87 86 88 87
OTHER ASIA 60973 86 (81..90) 81 83 91 87 82 87 86 85
INDIA 291215 83 (80..86) 81 81 89 86 80 84 84 82
BRAZIL 274896 83 (80..85) 81 85 91 87 76 79 84 83
PAKISTAN 27511 83 (75..91) 69 81 85 83 83 81 81 83
MEXICO 54997 81 (77..86) 76 83 89 85 75 79 82 80
IRAN 121035 78 (74..82) 76 79 89 84 70 79 79 78
OTHER AMERICAS 30787 77 (71..83) 70 86 88 82 78 73 81 77
ARGENTINA 40775 77 (72..82) 70 79 84 80 77 72 81 78
EGYPT 48649 75 (69..80) 68 74 89 83 65 78 75 74
OTHER AFRICA 90041 70 (65..74) 65 72 81 76 69 70 71 70
	   11	  
Notes to Table S4:  
 
All numbers are calculated based on papers published during 2015-2016. 
 
Column 1a: Location. 
 
Column 1b: Number of contributions based on which the edge factor in column (1c) is calculated. See notes to Table 
1. 
 
Column 1c: Edge factor for the baseline specification.  
 
Column 1d: Bootstrapped 95% confidence interval for the edge factor in the baseline specification. 
 
Column 2: When there are no observations for an (idea category, research area) pair for a location, the edge factor 
for that that (idea category, research area) pair is set to 0; in the baseline specification (shown in column 1c) the 
edge factor is set to the weighted average of the edge factor for all other (idea category, research area) pairs. 
 
Column 3: When the overall edge factor is calculated for a location, the weight of the edge factor for each (idea 
category, research area) pair is the location’s own number of papers linked to that (idea category, research area) pair; 
in the baseline specification (shown in column 1c) the weight is the number of papers from any location that are 
linked to that (idea category, research area) pair. 
  
Column 4: The vintage of each UMLS term is determined based on the earliest year of appearance of the UMLS 
term or any of its synonyms (as indicated in the UMLS); in the baseline specification (shown in column 1c) vintage 
is determined based on the earliest year of appearance of the UMLS term.  
 
Column 5: When the dummy variable that indicates the novelty of a contribution relative to other contributions in 
the comparison group is constructed, a 20% cutoff level is used, so that the 20% of the contributions with the most 
recent cohort are assigned the novel status; in the baseline specification (shown in column 1c) the corresponding 
cutoff is 5%.  
 
Column 6: Same as Column (5) but now a 10% cutoff is used. 
 
Column 7: Same as Column (5) but now a 1% cutoff is used. 
 
Column 8: The analysis includes all types of publications in MEDLINE; in the baseline specification (shown in 
column 1c) only original research papers are considered.  
 
Column 9: The analysis includes also those papers for which MEDLINE has either less than 200 characters of text 
or more than 5000 characters of text; in the baseline specification (shown in column 1c) only those original research 
papers are included for which the text information in MEDLINE falls within those bounds. 
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Table S5. Overall Scientific Frontier Positions of Nations by Time Period. 
 
(1a) (1b) (1c) (2a) (2b) (2c) (2d) (2e) (2f)
Location Number of 
Contributions
2015-6 1990-94 
with 
1990s 
weights
1995-9, 
with 
1990s 
weights
2000-4, 
with 
1990s 
weights
2005-9, 
with 
1990s 
weights
2010-4,
with 
1990s 
weights
2015-6,
with 
1990s 
weights
UNITED STATES 2853661 108 107 108 109 109 109 109
SOUTH KOREA 374227 107 82 87 102 106 105 107
SINGAPORE 52541 105 89 105 102 108 109 104
TAIWAN 177229 104 90 85 89 95 101 105
IRELAND 39495 103 74 84 97 100 106 99
BELGIUM 95644 102 101 101 104 108 107 106
ITALY 384029 102 94 95 95 99 102 103
CHINA 1734035 101 79 82 98 97 98 101
CANADA 375846 101 93 96 98 100 101 100
JAPAN 554589 100 95 96 100 101 101 102
UNITED KINGDOM 494917 100 103 104 103 103 104 101
NETHERLANDS 233631 100 93 94 99 103 102 100
GERMANY 539888 100 96 97 101 102 102 103
SWITZERLAND 123779 100 105 107 105 104 104 103
SAUDI ARABIA 34855 99 83 75 65 85 87 95
FINLAND 59534 99 95 95 96 93 96 99
NORWAY 63699 98 90 92 90 97 99 100
SOUTH AFRICA 43179 98 75 76 84 84 84 96
SPAIN 278504 98 79 85 90 92 96 99
CZECH REPUBLIC 44024 97 70 75 87 90 94 97
AUSTRALIA 320955 97 92 94 96 96 98 98
SWEDEN 138949 96 87 87 90 94 97 98
AUSTRIA 65039 96 99 98 99 102 99 99
DENMARK 105066 95 89 89 91 94 97 96
FRANCE 305065 95 97 96 97 101 99 97
POLAND 113074 93 59 68 73 77 87 92
THAILAND 40080 93 79 73 73 75 79 85
HUNGARY 28574 92 72 75 80 83 85 94
ISRAEL 76781 92 79 78 87 93 94 95
OTHER EUROPE 107712 90 74 73 76 77 82 89
NEW ZEALAND 38946 90 92 92 92 93 95 87
TURKEY 157825 90 70 67 72 69 82 86
RUSSIA 51759 89 57 68 68 65 81 89
CHILE 23794 89 49 62 74 74 85 89
GREECE 46646 89 71 78 78 80 84 90
MALAYSIA 37997 87 57 77 94 68 80 81
PORTUGAL 65523 86 81 82 74 88 93 84
OTHER ASIA 60973 86 70 64 70 69 76 85
INDIA 291215 83 57 61 65 68 74 78
BRAZIL 274896 83 81 74 74 75 77 79
PAKISTAN 27511 83 53 56 57 75 77 81
MEXICO 54997 81 73 69 70 73 74 79
IRAN 121035 78 32 36 56 66 72 74
OTHER AMERICAS 30787 77 81 84 71 77 74 70
ARGENTINA 40775 77 58 65 69 69 75 74
EGYPT 48649 75 49 67 62 65 67 71
OTHER AFRICA 90041 70 77 76 66 67 67 63
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Notes to Table S5:  
 
Column 1a: Location. 
 
Column 1b: Number of contributions based on which the edge factor in column (1c) is calculated. See notes to Table 
1. 
 
Weights below refer to how the edge factor for each (idea category, research area) pair is weighted when the overall 
edge factor for a location is calculated. When “2015-6 weights” are used, the weight for each (idea category, 
research area) pair is the total number of papers published during 2015-2016 that are linked to that (idea category, 
research area) pair.  
  
Column 1c: Edge factors for 2015-2016 (calculated using 2015-6 weights). 
 
Column 2a. Edge factors for 1998-1994, calculated using 1990s weights. 
 
Column 2b. Edge factors for 1995-1999, calculated using 1990s weights. 
 
Column 2c. Edge factors for 2000-2004, calculated using 1990s weights.  
 
Column 2d. Edge factors for 2005-2009, calculated using 1990s weights.  
 
Column 2e. Edge factors for 2010-2014, calculated using 1990s weights.  
 
Column 2f. Edge factors for 2015-2016, calculated using 1990s weights.  
 
